Gefitinib (ZD1839)

Catalog No.S1025

Molecular Weight(MW): 446.90

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

Cited by 98 Publications

Cell Death Dis, 2019, 10(4):283

PubMed: 30911072 ( click the link to review the publication )

Life Sci, 2019, 224:23-32

PubMed: 30902544 ( click the link to review the publication )

Exp Ther Med, 2019, 17(1):953-959

PubMed: 30651886 ( click the link to review the publication )

Nature, 2017, 547(7664):453-457

PubMed: 28678785 ( click the link to review the publication )

Eur J Pharmacol, 2017, 821:21-28

PubMed: 29277715 ( click the link to review the publication )

Oncol Rep, 2017, 37(2):1212-1218

PubMed: 27959426 ( click the link to review the publication )

Nature, 2016, 534(7609):647-51

PubMed: 27338794 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

J Pathol, 2016, 239(3):320-34

PubMed: 27102572 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 10.1016/j.bbagen.2016.05.011

PubMed: 27180173 ( click the link to review the publication )

Exp Cell Res, 2016, 344(2):194-200

PubMed: 27180268 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):713-22

PubMed: 25934077 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.16

PubMed: 25656847 ( click the link to review the publication )

Nat Commun, 2015, 6:6377

PubMed: 25758528 ( click the link to review the publication )

J Thorac Oncol, 2015, 10.1097/JTO.0000000000000500

PubMed: 25658629 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2789

PubMed: 25948633 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560

PubMed: 25964297 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2015, 112(6):1839-44

PubMed: 25605917 ( click the link to review the publication )

Cell Rep, 2015, 10.1016/j.celrep.2015.04.049

PubMed: 26027934 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):527-43

PubMed: 25454348 ( click the link to review the publication )

Mol Cell Proteomics, 2015, 10.1074/mcp.M115.049783 mcp.M115.049783.

PubMed: 25953087 ( click the link to review the publication )

J Chromatogr A, 2015, 10.1016/j.chroma.2015.04.055

PubMed: ( click the link to review the publication )
Toxicol Appl Pharmacol, 2015, 10.1016/j.taap.2015.05.001

PubMed: 25981168 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2015, 10.1016/j.ijrobp.2015.01.026

PubMed: 25823448 ( click the link to review the publication )

Nature, 2014, 508(7494):118-22

PubMed: 24670642 ( click the link to review the publication )

Mol Cell, 2014, 55(6):904-15

PubMed: 25219500 ( click the link to review the publication )

Cancer Res, 2014, 74(1):253-62

PubMed: 24165158 ( click the link to review the publication )

Int J Cancer, 2014, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )

Oncogene, 2014, 33(19):2495-503

PubMed: 23728339 ( click the link to review the publication )

Oncogene, 2014, 33(35):4385-95

PubMed: 24096476 ( click the link to review the publication )

MBio, 2014, 5(4):e01340-14

PubMed: 25096879 ( click the link to review the publication )

Cancer Lett, 2014, 342(1):82-91

PubMed: 24001610 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Mol Oncol, 2014, 10.1016/j.molonc.2014.05.005

PubMed: 24908424 ( click the link to review the publication )

Mol Oncol, 2014, 9(1):260-9

PubMed: 25226813 ( click the link to review the publication )

Cell Oncol , 2014, 37(5):377-86

PubMed: 25228008 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02393-14

PubMed: 24663025 ( click the link to review the publication )

Colloids and Surfaces B: Biointerfaces, 2014, 123:61-7

PubMed: 25216919 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(3):318-22

PubMed: 24335466 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3808-17

PubMed: ( click the link to review the publication )

Am J Physiol Renal Physiol, 2014, 307(4):F435-44

PubMed: 24990892 ( click the link to review the publication )

Cancer Chemoth Pharm, 2014, 74(3):511-20

PubMed: 25038613 ( click the link to review the publication )

PLoS One, 2014, 9(4):e93651

PubMed: 24695557 ( click the link to review the publication )

PLoS One, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )
PLoS One, 2014, 9(12):e114000

PubMed: 25486409 ( click the link to review the publication )

PLoS One, 2014, 9(5):e97719

PubMed: 24874286 ( click the link to review the publication )

Horm Cancer, 2014, 289(24):17195-202

PubMed: 24778185 ( click the link to review the publication )

Exp Mol Pathol, 2014, 97(1):154-165

PubMed: 24984270 ( click the link to review the publication )

Langenbecks Arch Surg, 2014, 10.1007/s00423-014-1235-1

PubMed: 25070024 ( click the link to review the publication )

Korean J Parasitol, 2014, 52(4):439-41

PubMed: 25246725 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2014, 88(4):947-54

PubMed: 24606853 ( click the link to review the publication )

University of Alberta, 2014, Yahya Muhammad Fiteih

PubMed: ( click the link to review the publication )

Guangxi Medical University, 2014, Suning Huang

PubMed: ( click the link to review the publication )

JBUON , 2014, 19(2): 466-473

PubMed: ( click the link to review the publication )

Ann Oncol, 2013, 24(2):362-9

PubMed: 22967992 ( click the link to review the publication )

J Clin Endocrinol Metab, 2013, 98(6):2502-12

PubMed: 23559083 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(2):444-53

PubMed: 24258346 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(11):2541-58

PubMed: 24026012 ( click the link to review the publication )

Carcinogenesis, 2013, 34(9):1994-9

PubMed: 23677069 ( click the link to review the publication )

Radiother Oncol, 2013, 108(3):473-8

PubMed: 23891090 ( click the link to review the publication )

J Biol Chem, 2013, 288(48):34930-42

PubMed: 24142702 ( click the link to review the publication )

Drug Metab Dispos, 2013, 10.1124/dmd.113.054189

PubMed: 24335466 ( click the link to review the publication )

Prostate, 2013, 73(13):1453-61

PubMed: 23765757 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82625

PubMed: 24349321 ( click the link to review the publication )

Exp Mol Pathol, 2013, 94(2):386-97

PubMed: 23399805 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2013, 2013:243859

PubMed: 23533466 ( click the link to review the publication )

Oncotarget, 2013, 4(10):1698-1711

PubMed: 24091605 ( click the link to review the publication )

Tuberc Respir Dis, 2013, 75(3):95-103

PubMed: 24101933 ( click the link to review the publication )
Nature, 2012, 483(7387):100-3

PubMed: 22281684 ( click the link to review the publication )

Cell, 2012, 151(5):937-50

PubMed: 23178117 ( click the link to review the publication )

Cancer Discov, 2012, 2(10):934-47

PubMed: 22961667 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):1908-16

PubMed: 22722337 ( click the link to review the publication )

Int J Cancer, 2012, 131(12):2961-9

PubMed: 22514082 ( click the link to review the publication )

Int J Cancer, 2012, 131(2):334-43

PubMed: 21858806 ( click the link to review the publication )

Oncogene, 2012, 32(34):4034-42

PubMed: 22964644 ( click the link to review the publication )

Cancer Lett, 2012, 321(2):187-94

PubMed: 22343320 ( click the link to review the publication )

Cancer Sci, 2012, 103(1):7-16

PubMed: 21951556 ( click the link to review the publication )

Biochem Pharmacol, 2012, 84(4):425-31

PubMed: 22634404 ( click the link to review the publication )

Int J Mol Sci, 2012, 13(9):12000-16

PubMed: 23109896 ( click the link to review the publication )

Int J Oncol, 2012, 41(3):869-75

PubMed: 22752005 ( click the link to review the publication )

Cancer Res Treat, 2012, 44(3):202-9

PubMed: 23091447 ( click the link to review the publication )

PLoS One, 2012, 7(9):e42441

PubMed: 22957020 ( click the link to review the publication )

PLoS One, 2012, 7(12):e51549

PubMed: 23272116 ( click the link to review the publication )

Oncotarget, 2012, 2(12):1134-44

PubMed: 22193779 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Mol Syst Biol, 2011, 7:486

PubMed: 21525872 ( click the link to review the publication )

Oncogene, 2011, 30(6):737-50

PubMed: 20890302 ( click the link to review the publication )

Antivir Res, 2011, 89(1):64-70

PubMed: 21094187 ( click the link to review the publication )

J Immunother, 2011, 34(4):372-81

PubMed: 21499124 ( click the link to review the publication )

Mol Biosyst, 2011, 7(12):3223-33

PubMed: 21956701 ( click the link to review the publication )

Exp Mol Pathol, 2011, 91(1):400-10

PubMed: 21565184 ( click the link to review the publication )

Vet Comp Oncol, 2011, 11(2):124-39

PubMed: 22235915 ( click the link to review the publication )
Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Carcinogenesis, 2010, 31(11):1948-55

PubMed: 20837598 ( click the link to review the publication )

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

Features

A potent EGFR tyrosine kinase inhibitor.

Targets

Tyr1173 (NR6W cells) ^[1]	Tyr1173 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6W cells) ^[1]
26 nM	37 nM	37 nM	57 nM

In vitro

Gefitinib effectively inhibits all tyrosine phosphorylation sites on EGFR in both the high and low-EGFR-expressing cell lines including NR6, NR6M and NR6W cell lines. The phosphorylation sites Tyr1173 and Tyr992 are less sensitive requiring higher concentrations of Gefitinib for inhibition. Gefitinib effectively blocks the phosphorylation of PLC-γ, with IC50 of 27nM, in NR6W cells. The NR6wtEGFR and NR6M cell lines has low levels of PLC-γ phosphorylation but the level in the NR6M cell line is more resistant to inhibition by Gefitinib with IC50 of 43 nM and 369 nM, respectively. Gefitinib inhibits Akt phosphorylations, with IC50 of 220 and 263nM, in the low-EGFR- and -EGFRvIII-expressing cell lines, respectively. Gefitinib in the dose range from 0.1 to 0.5μM significantly facilitates, rather than abrogates, colony formation of NR6M cells. However, at a concentration of 2 μM Gefitinib completely blocks NR6M colony formation. Gefitinib rapidly and in a dose-dependent manner inhibits EGFR and ERK phosphorylation up to 72 hours after EGF stimulation in both the high- and low-EGFR-expressing cell lines. ^[1] Gefitinib is the monolayer growth of these EGF-driven untransformed MCF10A cells with an IC50 of 20 nM. ^[2] The combination of Gefitinib (0.2 μM and 0.5 μM) with irradiation lead to a significant growth inhibition in LoVo cells, compared with radiation alone.. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
KB	NWXOOpdrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\1TWM2OD1yLkC1OEDPxE1?	NYTGcFBoOTZ3MU[0O\|M>
NIH3T3	NFu4[3VHfW6ldHnvckBCe3OjeR?=	NI\kSVQxNjJizszN	MUiyJIg>	MX3EUXNQ	MXfJcohq[mm2aX;uJI9nKEWJRjDzeIlufWyjdHXkJIh2dWGwIHXyZmIyKGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODF2NDFOwG0>	MYKxOlQ5ODJ6NB?=
COS7	NWfjXJFtTnWwY4Tpc44hSXO\|YYm=	Mk\XPVYh\|ryP			NEnSTG9KdmirYnn0bY9vKG:oIHj1cYFvKEqDS{KgWlYyP0ZibYX0ZY51KGW6cILld5Nm\A>?	MnLuNVcyPzh5MkK=
A549	NYK3S45PS3m2b4TvfIlkKEG\|c3H5		M{SzNVk3KGh?	M4LCfWROW09?	NYXy[W9NUUN3ME2xN{42QSEQvF2=	MYWxPFMyOzhyNx?=
K562	MVPDfZRwfG:6aXOgRZN{[Xl?		NIrXZ3A6PiCq	MoP5SG1UVw>?	NWGxT\|hRUUN3ME25MlM3KM7:TR?=	NH[0bYwyQDNzM{iwOy=>
MDA-MB-231	M{HaemN6fG:2b4jpZ{BCe3OjeR?=		NU\kbI84QTZiaB?=	MmPtSG1UVw>?	M4XKTGlEPTB;M{[uOlEh\|ryP	NHvPbmsyQDNzM{iwOy=>
MOLT4	M2qzfWN6fG:2b4jpZ{BCe3OjeR?=		M2n4NVk3KGh?	MWXEUXNQ	MUDJR\|UxRTF3LkCyJO69VQ>?	MlrUNVg{OTN6MEe=
MCF7	M1fleGN6fG:2b4jpZ{BCe3OjeR?=	MYK1NEDPxE1?	M3L4VVczKGh?		MXXJR\|UxRTF{LkC1JO69VQ>?	NImwXXYyQDd5MUixPS=>
BT474	Mn;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXKz[HB7PzJiaB?=		Mn25RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCEVES3OEBk\WyuczDveoVz\XiycnXzd4lv\yCHUlLiNkB4cXSqIFXDOVAhd2ZiMD6zJO69VQ>?	NUjzcnQ4OTlyMki0NlQ>
HN5	MnPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mk\IO\|IhcA>?		MXzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiQNTDj[YxteyCxdnXy[ZhxemW\|c3nu[{BGT0[UIIfpeIghTUN3MDDv[kAxNjBzIN88US=>	NG\r[IYyQTB{OESyOC=>
BA/F3	NEHEeXNEgXSxdH;4bYMhSXO\|YYm=		NHnwWlk4OiCq		NF3LdmtEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFXHSnIhVDh3OGKgcZV1[W62IIfpeIghUUN3MDDv[kAxNjBzMEig{txO	MmLjNVkzOzl{Mkm=
NIH3T3	MnrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIXGSVg4OiCq		M1zrSmdzd3e2aDDpcohq[mm2aX;uJI9nKG2xdYPlJG5KUC9\|VEOgZ4VtdHNiZYjwdoV{e2mwZzDldmIzKGenbnWge4l1cCCLQ{WwJI9nKDBwNUSg{txO	NVzXU\|JOOTl4NkWzO\|c>
MCF7 MX	NUeyd45TTnWwY4Tpc44hSXO\|YYm=		MlflN\|AhdWmw		MXHJcohq[mm2aX;uJI9nKEKFUmCg[ZhxemW\|c3XkJJdqfGhiSVO1NEBw\iBzLkGg{txO	M{XD[\|E6QTN{OU[w
A431	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnHNVAh\|ryP	NV:3fG1GPzJiaB?=		MXfHTVUxRTBwNUG0JO69VQ>?	MXGxPVk3QTR4NR?=
A431	Mlu0T4lv[XOnIFHzd4F6	Ml3CNE4yKM7:TR?=	NHrkT44yKGh?		NVrRZWx2UW6qaXLpeIlwdiCxZjDFS2YucW6mdXPl[EBGT0[UIIDoc5NxcG:{eXzheIlwdg>?	M2HPSVE6QTZ7NE[1
A431	NXLyVYNpU2mwYYPlJGF{e2G7	MlfqNVAxKM7:TR?=	NFH0cVEyOCCvaX6=		Mni4VJJwdG:wZ3XkJIlvcGmkaYTvdpkh[WO2aY\peJkhd2ZiRVfGMYlv\HWlZXSgSWdHWiCyaH;zdIhwenmuYYTpc44>	NI\hfXcyQTl4OUS2OS=>
Sf9	M1jEUGtqdmG\|ZTDBd5NigQ>?		MXGxNEBucW5?	MkHkSG1UVw>?	M2fWe2lvcGmkaYTpc44hd2ZiRVfGVkBmgHC{ZYPz[YQh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBz\WOncITvdkBifXSxcHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlA{OyEQvF2=	MmTJNlAxPTZ2MkW=
NCI-H1975	NVP6dYZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\DUm42KM7:TR?=	NHnTVos4OiCq		MYXJR\|UxRThwMk[g{txO	MWCyNFE2OTZ5MB?=
NCI-H1975	Mnu2T4lv[XOnIFHzd4F6	MkXsNVAh\|ryP			MkDyTY5pcWKrdHnvckBw\iCHR1\SJIF2fG:yaH;zdIhwenmuYYTpc44>	MYqyNFE2OTZ5MB?=
NCI-H1975	MnWwSpVv[3Srb36gRZN{[Xl?	M2TBRlExKM7:TR?=			NETEdpVKdmirYnn0bY9vKG:oIFXSRmIzKGG3dH;wbI9{eGixconsZZRqd25?	Mny3NlAyPTF4N{C=
NCI-H1975	M2j6VWZ2dmO2aX;uJGF{e2G7	MXW1JO69VQ>?	NYfPflg5PDhiaB?=		NGXOT5lKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHHzd4V{e2WmIHHzJIFkfGm4YYTpc44hd2ZiY3HzdIF{\S1\|	NF3uOYszODF3MU[3NC=>
A375	Mn;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnLROFghcA>?		NF\abG5KSzVyPUKwMlU2KM7:TR?=	MmfPNlA{ODR3M{e=
SMMC7721	M2K2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MofnOFghcA>?		MkDoTWM2OD1\|Mz6xNkDPxE1?	M4fXRVIxOzB2NUO3
DU145	NYW3dI1RS3m2b4TvfIlkKEG\|c3H5		NV;MTpUxPSCm	NWn0bIhrTE2VTx?=	NHf3VWpKSzVyPUSyMlE4KM7:TR?=	Mmn2NlA1PjZ3NUW=
MIAPaCa2	NIHlenBEgXSxdH;4bYMhSXO\|YYm=		NUftTYJGPSCm	NGmwU45FVVOR	M3X5ZWlEPTB;NUCuOlIh\|ryP	MoDBNlA1PjZ3NUW=
PANC1	NXPBW5dDS3m2b4TvfIlkKEG\|c3H5		MXi1JIQ>	NHzoWHFFVVOR	NVv2UIw{UUN3ME20NE41OiEQvF2=	M4Dv[VIxPDZ4NUW1
PC9	M1;LSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4HmcmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgSWdHWi2mZX\pZ4lmdnRiaIXtZY4hWEN7IHPlcIx{KHerdHigSWM2OCCxZjCwMlAyPyEQvF2=	M4WyTlIyOjB6OECy
PC9	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWL0d\|dwSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBoem:5dHitdoV{cXO2YX70JIh2dWGwIGDDPUBk\WyuczDlfJBz\XO\|aX7nJGVITlJiRUe0On9CPzVyL2S3PVBOKG23dHHueEB4cXSqIFXDOVAhd2ZiNzFOwG0>	M2PPbVIyOjB6OECy
PC3	NGC2NIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\1VW0yOCEQvF2=	MVK3NkBp	Mlz4SG1UVw>?	M2rJ[WlEPTB;Nz60JO69VQ>?	MWGyNVM2OzV2Nh?=
MDA-MB-468	M{DVc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPkVVYyODBizszN	MmPmOFghcA>?	MoTCSG1UVw>?	MWrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eR?=	NGXoWIozOTR{OU[zNi=>
Plasmodium falciparum					M4XYVpFJXFNicILv[oltcW6pIH\vdkBqdmirYnn0c5J{KG:oIGDsZZNud2SrdX2g[oFt[2myYYL1cUBxem:uaX\ldoF1cW:w	NVrQV3RMOjF6MUewOFU>
NCI-H1993	M2K5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEixN3o4OiCq	Mn31SG1UVw>?	M1PuSGlEPTB;MD6xJO69VQ>?	NEWxcXkzOTlzNkSzNy=>
NCI-H292	NXPSOHpxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFv2R3Q4OiCq	NXLxN4VVTE2VTx?=	NWSzfGp[UUN3ME2wMlAzKM7:TR?=	MonINlE6OTZ2M{O=
A431	MWjLbY5ie2ViQYPzZZk>		NVOySll6OiCq	MkLGSG1UVw>?	NH;UVHZKdmirYnn0bY9vKG:oIFXHSnIheGixc4Doc5J6dGG2aX;uJIlvKEWJRj3zeIlufWyjdHXkJIh2dWGwIFG0N\|Ehf2m2aDDJR\|UxKG:oIECuNFAyKM7:TR?=	NXn2WZBsOjJzMEGxN\|I>
MCF7	NInpbXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVOxNFDDqM7:Zz;tUC=>	M{DaTlQ5KGh?	MVTEUXNQ	NHrFXItCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgc5ZmemW6cILld5NqdmdiRVfGVkBo\W6nIIfpeIghUUN3MDDv[kAyOi5yNTFOwG0>	M2[1SFIzOTF7MUOw
BT474	MVTDfZRwfG:6aXOgRZN{[Xl?	MWKxNEDPxE1?	Ml7GOFghcA>?		MVfDfZRwfG:6aXPpeJkh[WejaX7zeEB{\XK3bT3zeIFzfmWmIHj1cYFvKEKWNEe0JINmdGy\|	MYiyNlE{QDNyOB?=
MCF7	MWLDfZRwfG:6aXOgRZN{[Xl?	NILBVHcyOCEQvF2=	MUK0PEBp		NYKwdnU2S3m2b4TvfIlkcXS7IHHnZYlve3Ric3XyeY0ue3Sjco\l[EBpfW2jbjDNR2Y4KGOnbHzzJI93\XJvZYjwdoV{e2mwZzDFdoJDOiClZXzsdy=>	M3ToPFIzOTN6M{C4
HCC827	M3XQSGtqdmG\|ZTDBd5NigQ>?	MoqzNE4yOjVizszN	M1nyTVI1KGh?	MmLPSG1UVw>?	M2\sOGlvcGmkaYTpc44hd2ZiRVfGVkBl\WxiRUe0Ok1CPzVyIH31eIFvfCC\MUC2PEBifXSxcHjvd5Bpd3K7bHH0bY9v	NGLSVXozOjN\|OUO0Ni=>
HCC827	M3GyfmtqdmG\|ZTDBd5NigQ>?	NWH5bGEyOC5zMkWg{txO	NXTNVXBmOjRiaB?=	M4S1TmROW09?	NFH6TYxKdmirYnn0bY9vKG:oIFXHSnIh\GWuIFW3OFYuSTd3MDDteZRidnRvbXXkbYF1\WRiRYLrJJBpd3OyaH;yfYxifGmxbh?=	NHTWWHgzOjN\|OUO0Ni=>
HCC827	NVfC[2J6U2mwYYPlJGF{e2G7	M{DnflAvOTJ3IN88US=>	MWqyOEBp	MVzEUXNQ	MoTrTY5pcWKrdHnvckBw\iCHR1\SJIRmdCCHN{S2MWE4PTBibYX0ZY51NW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25?	M2P6c\|IzOzN7M{Sy
A431	NGqzWYhMcW6jc3WgRZN{[Xl?	NGC5cZAyODBizszN	NXzwUHJqOzBibXnu		MoO0TY5pcWKrdHnvckBw\iCHR1\SJIRmemm4ZXSg[pJwdSCqdX3hckBCPDNzIHPlcIwhdWWvYoLhcoUh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBxd2y7LVfseU1VgXJicHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCxMlA5KM7:TR?=	MoHNNlI3QTh5OEK=
H460	NW\mZ3pXS3m2b4TvfIlkKEG\|c3H5		MYK3NkBp		NHrwPJFKSzVyPUWuOVkh\|ryP	NXu5[5c3OjJ5Mke0OFk>
HT-29	NHHYNJZEgXSxdH;4bYMhSXO\|YYm=		M4e4Z\|czKGh?		NGfZV45KSzVyPUOuN\|Yh\|ryP	NV7sOoRzOjJ5Mke0OFk>
SGC7901	NYjmTHBpS3m2b4TvfIlkKEG\|c3H5		NEO2T404OiCq		MkD0TWM2OD1zMD6yOkDPxE1?	NXS4PG5MOjJ5Mke0OFk>
A498	MmDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVrpRlJlSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOFk5KGOnbHzzJIV5eHKnc4PpcochTUeIUjDhcoQhW1KFIIfpeIghUUN3MDDv[kA5NjZizszN	NWTiOHh3OjJ6MUi4OFg>
Calu3	MkTiR5l1d3SxeHnjJGF{e2G7	M2\yeVExKM7:Zz;tUC=>	MX[3NkBp		MUXJR\|UxRTFwNjFOwG0>	M2L2XFI{OTF4MU[4
FADU	MkDIR5l1d3SxeHnjJGF{e2G7	M1XXfFExKM7:Zz;tUC=>	MU[3NkBp		NWfpZpVqUUN3ME2wMlA2KM7:TR?=	M2TWUVI{OTF4MU[4
HCC827	MV;DfZRwfG:6aXOgRZN{[Xl?	Mly5NVAh\|rypL33M	Mn\4O\|IhcA>?		NX;lSXpMUUN3ME2wMlAxOTVizszN	NUf2V\|ZrOjNzMU[xOlg>
PC9	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmThNVAh\|rypL33M	NHf6R4c4OiCq		NVXkNotEUUN3ME2wMlAyPCEQvF2=	MnLINlMyOTZzNki=
Sf9	MV;LbY5ie2ViQYPzZZk>		NWnUZYpTOSCq	MXHEUXNQ	NI[yVFhKdmirYnn0bY9vKG:oIHj1cYFvKEeVVD30ZYdo\WRiRVfGVkBNQDN2UjDteZRidnRiZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAxNjBzNTFOwG0>	M3S2PFI{PjFzNkmx
16HBE14o-	NIG4O2FEgXSxdH;4bYMhSXO\|YYm=	MkTENVAh\|ryP	NH7CTXg4OiCq	MnLYSG1UVw>?	M2K5fGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJFE3UEKHMUTvMUBk\WyuczDoZZJjd3Krbnege4lt\CC2eYDlJGVITlJiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDF{LkexJO69VQ>?	MVmyN\|Y3QDR2MR?=
NCI-H1975	MWLDfZRwfG:6aXOgRZN{[Xl?	NHOzT20yOCEQvF2=	M13wXVczKGh?	NWPvOotWTE2VTx?=	MWfDfZRwfG:6aXPpeJkh[WejaX7zeEBo\W[rdHnubYIuemW\|aYP0ZY51KGi3bXHuJG5EUS2KMUm3OUBk\WyuczDoZZJjd3KrbnegSWdHWiCOOEW4Vk9VPzlyTTDkc5VjdGVibYX0ZY51KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIIfpeIghUUN3MDDv[kA3NjlzNzFOwG0>	MnPONlM3Pjh2NEG=
16HBE	NYi2NGk4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIXTNpU4OiCq	MlrGSG1UVw>?	MmXCRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiBzNljCSUBk\WyuczDlfJBz\XO\|aX7nJJdqdGRidInw[UBGT0[UIIfpeIghUUN3MDDv[kAyNjZyMTFOwG0>	NHuyfXQzOzd7MkOxPC=>
16HBE	NHziT5pHfW6ldHnvckBCe3OjeR?=	NG\6N2IyODBizszN	NX7ITVE5OTVyIH3pci=>	MV3EUXNQ	NYLJV3EzUW6mdXP0bY9vKG:oIH7peJJq[yCxeHnk[UBxem:mdXP0bY9vKGmwIHj1cYFvKDF4SFLFJINmdGy\|IHX4dJJme3Orbnege4lt\CC2eYDlJGVITlJ?	M4X2VFI{Pzl{M{G4
A549	NXm4U5N1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NY\XSFBbPzJiaB?=	Mn[ySG1UVw>?	MWrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IIfpcIQhfHmyZTDFS2ZTN2tvUnHzJIRmeGWwZHXueEBpfW2jbjDBOVQ6KGOnbHzzJJdqfGhiSVO1NEBw\iB2Lk[yOkDPxE1?	MUKyN\|c6OjNzOB?=
SH-SY5Y	MXLDfZRwfG:6aXOgRZN{[Xl?		M1n4PFczKGh?		Mk\ZTWM2OD1zOD6yNUDPxE1?	MlzTNlM5PzF7MEm=
LoVo	M17DRmtqdmG\|ZTDBd5NigQ>?		M2jB[VIhKGh?	Mk\QSG1UVw>?	NXrlZmNvUW6qaXLpeIlwdiCxZjDFS2ZTKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wOlIh\|ryP	MnTTNlM6OzB7OUS=
PC9	M2ToZ2tqdmG\|ZTDBd5NigQ>?		MoXBNkBp	MUPEUXNQ	MlfRTY5pcWKrdHnvckBw\iCHR1\SJIV5d25iMUmg[IVt\XSrb36gZYN1cX[jdHnu[{BufXSjboSgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIGDDPUBk\WyuczD3bZRpKEmFNUCgc4YhOC5yMEi3JO69VQ>?	MWKyN\|k{ODl7NB?=
HCC827	NVXwWZVCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Ml:0O\|IhcA>?		NInDcFFKSzVyPUCuNFEzKM7:TR?=	MYmyN\|k4OzF4OB?=
A549	M4XVfGtqdmG\|ZTDBd5NigQ>?	NIr4PJgyKM7:TR?=	Mnz0NUBp	MnjlSG1UVw>?	MmTvTY5pcWKrdHnvckBw\iCHR1\SJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR\|UxKG:oIECuNFM6QSEQvF2=	NV\rS2NiOjN7OEizOVQ>
A549	MXnGeY5kfGmxbjDBd5NigQ>?	NITCUooyKM7:TR?=	NFTqTXQyKGh?	NITxTYhFVVOR	MkHFR4VtdHWuYYKgeZB1[Wun	NEjufm8zOzl6OEO1OC=>
HCC827	MoPtT4lv[XOnIFHzd4F6	NVvteZV6OC53IN88US=>	MmDNNkBp	MWLEUXNQ	MmnjTY5pcWKrdHnvckBw\iCHR1\SJJBpd3OyaH;yfYxifGmxbjDpckBo\W[rdHnubYIuemW\|aYP0ZY51KGi3bXHuJGhESzh{NzDj[Yxtew>?	MmHTNlM6QTN\|Mki=
HCC827	MUfGeY5kfGmxbjDBd5NigQ>?	NUXHe4xnOC53IN88US=>	NVn5VmFqOiCq	MlThSG1UVw>?	M{jF[2lvcGmkaYTpc44hd2ZiYz3N[ZQheGixc4Doc5J6dGG2aX;uJIlvKGenZnn0bY5q[i2{ZYPpd5RidnRiaIXtZY4hUEOFOEK3JINmdGy\|	MoXtNlM6QTN\|Mki=
HCC827	NHy5Z5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvyRnd{OTBizszN	M2LoN\|czKGh?	MYLEUXNQ	MoHERY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDn[YZqfGmwaXKtd4Vve2m2aY\lJIh2dWGwIFjDR\|gzPyClZXzsd{Bp[XKkb4LpcochTUeIUjDFO\|Q3KHSxIFG3OVAh\GWuZYTpc44hf2m2aDDJR\|UxKG:oIECuNFA2QDFizszN	Mni3NlQxPTN4N{S=
A431	MXfLbY5ie2ViQYPzZZk>	MYixNFAh\|ryP	MmDhN\|AhdWmw		NXXqTotlUW6qaXLpeIlwdiCxZjDFS2ZTKGmwIIPo[YQhdWWvYoLhcoUhfmW\|aXPs[ZMhf2m2aDDJR\|UxKG:oIEGuNUDPxE1?	NUXD[FZ3OjRyOUS0N\|I>
BCRP-MDCK2	NH;IdYFHfW6ldHnvckBCe3OjeR?=	MYCxMlgh\|ryP	MYm3NkBp	MUPEUXNQ	MVzJcoNz\WG\|ZTDv[kBxdGG\|bXGgcYVu[nKjbnWg[ZhxemW\|c3nvckBw\iCEQ2LQJIV5eHKnc4PpcochemWyb4L0[ZIh\2WwZTDHSnA>	MXWyOFE5PDJzMx?=
BCRP-MDCK2	NGexRpFHfW6ldHnvckBCe3OjeR?=	M4X2N\|EvQCEQvF2=	NFzIZVE4OiCq	NVLGTZpZTE2VTx?=	MlHvVoVlfWO2aX;uJI9nKHCuYYPtZUBu\W2kcnHu[UBmgHC{ZYPzbY9vKG:oIFLDVnAh\XiycnXzd4lv\yC{ZYDvdpRmeiCpZX7lJGdHWA>?	M{nVR\|I1OTh2MkGz
MDCK	MVrDfZRwfG:6aXOgRZN{[Xl?		NWm3OVloPzJiaB?=	MYHEUXNQ	MkD5S2k2OD1zLkS1JO69VQ>?	Ml7vNlQyQDR{MUO=
MDCK2	NY\hNpFsTnWwY4Tpc44hSXO\|YYm=	NWDCeZQ1OS56IN88US=>	MVK3NkBp	NGG5b5RFVVOR	MnLDTY5pcWKrdHnvckBw\iCqdX3hckBDS1KSIHX4dJJme3OnZDDhd5Nme3OnZDDhd{BJd2WlaIP0JFM{OzR{IHHjZ5VufWyjdHnvckB4cXSqIFnDOVAhd2ZiMz6xPUDPxE1?	NXO5cFY5OjRzOESyNVM>
A431	NF7FR5NEgXSxdH;4bYMhSXO\|YYm=		MYK3NkBp	M1;ZeGROW09?	NYLPfphTS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTR\|MTDj[YxteyCneIDy[ZN{cW6pIFXHSnIhf2m2aDDJR\|UxKG:oIECuOVUh\|ryP	NV[y[WdyOjR2MUGxNlM>
Calu3	NFL6NlVEgXSxdH;4bYMhSXO\|YYm=		MVu3NkBp	MXTEUXNQ	MX3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDZYx2OyClZXzsd{BmgHC{ZYPzbY5oKEiHUkKge4l1cCCLQ{WwJI9nKDBwOUmg{txO	NITOb\|EzPDRzMUGyNy=>
KB	M3HBbmtqdmG\|ZTDBd5NigQ>?	M2fGWlExKM7:TR?=	NHHCTogyKGh?	MkTNSG1UVw>?	M4jDWGlvcGmkaYTpc44hd2ZiRVfGMZN1cW23bHH0[YQh[XW2b4Doc5NxcG:{eXzheIlwdiCxZjDFS2ZTKHerdHigTWM2OCCxZjCwMlAzPSEQvF2=	NULZWY5WOjR2MUGxNlM>
BEAS2B	M3HCWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MojYOVAh\|ryP	M2q1OlczKGh?	MlTUSG1UVw>?	MX;JR\|UxRTF\|Lkm0JO69VQ>?	NYLPXmN[OjR4MEe1PVE>
NCI-H1975	MYLGeY5kfGmxbjDBd5NigQ>?	NX;VenJ6OTByIN88US=>	Mk\CNVUxKG2rbh?=	NGjSN5VFVVOR	MnTJTY5lfWO2aX;uJI9nKE6RIIDyc4R2[3Srb36gbY4hcHWvYX6gUmNKNUhzOUe1JINmdGy\|IHjhdoJwemmwZzDFS2ZTKEx6NUjSM3Q4QTCPIH31eIFvfA>?	M{P0UlI1PjB5NUmx
Hela	M{nSbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWjVTHVQOjRiaB?=	NUPhT5dxTE2VTx?=	M2LxOmlEPTB;Mj62O{DPxE1?	MUmyOFc{OTJ6MR?=
HepG2	M4C5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2LpXFI1KGh?	NV\zU4g4TE2VTx?=	Mo\tTWM2OD14LkSyJO69VQ>?	NUHNOVF5OjR5M{GyPFE>
Sf9	MVPLbY5ie2ViQYPzZZk>		M3rhdFExKG2rbh?=	NYq4d404TE2VTx?=	M{THfmlvcGmkaYTpc44hd2ZiYYX0c5Bpd3OyaH;yfYxifGmxbjDv[kBz\WOxbXLpcoFvfCCqaYOteIFo\2WmIFXHSnIhMGGvaX7vJIFkcWRiNkS1MVEyQDZrIHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOC5yMjFOwG0>	M3P3TFI1PzNzMkix
SW620	MoX4R5l1d3SxeHnjJGF{e2G7		MWC0PEBp	MnLmSG1UVw>?	NULTSVhRUUN3ME2yPE4zKM7:TR?=	NVrpNmhQOjR7MEC1PVQ>
HCC827	MVPGeY5kfGmxbjDBd5NigQ>?	MV:wMlUh\|ryP	M2TjWVIhcA>?	M2HaUmROW09?	M{L1VoRw\XNibn;0JIlvcGmkaYSgZ{1O\XRiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCDS2SgdIhwe3Cqb4L5cIF1cW:w	NF3VdmYzOzl7M{OyPC=>
HCC827	MkPmSpVv[3Srb36gRZN{[Xl?	M3jE[\|AvPSEQvF2=	MlG5NkBp	M3vhNWROW09?	MV3kc4V{KG6xdDDpcohq[mm2IHOtUYV1KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YheDR2L{SyJJBpd3OyaH;yfYxifGmxbh?=	MnPNNlM6QTN\|Mki=
HCC827	MVjDfZRwfG:6aXOgRZN{[Xl?	NUjGNmoyOC53IN88US=>	NEHnRYQ4OiCq	M3\MPWROW09?	NUXmS2VpcGG\|IH7vJIN6fG:2b4jpZ4l1gQ>?	M{\5WFI{QTl\|M{K4
NCI-H1975	MYrGeY5kfGmxbjDBd5NigQ>?	NEjtcZUyOCEQvF2=	MnvlPEBp	NVm0WlBGTE2VTx?=	NIToS2tld2W\|IH7veEBqdmirYnn0bUBGT0[UIHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCHUlugdIhwe3Cqb4L5cIF1cW:w	NGj1T\|UzOzFzNkG2PC=>
A431	Mm\CT4lv[XOnIFHzd4F6	M{i5WFEh\|ryP	NEnOWnUyKGh?	MVXEUXNQ	M{HOSYhieyCwbzDpdpJmfmW{c3nicIUhcW6qaXLpeIlwdiCxZjDFS2ZTKGG3dH;wbI9{eGixconsZZRqd25?	M33uVVI1QTByNUm0
LNCaP	NVm5c\|RRTnWwY4Tpc44hSXO\|YYm=	MUWxNEDPxE1?	MUCybEBweiB2IHi=	NUXLVnF3TE2VTx?=	MVvkc4V{KG6xdDDpcohq[mm2IHH1eI9xcG:\|cHjvdplt[XSrb36gc4YhcW2vdX7vdJVzcW[rZXSg[oxi\y22YXfn[YQhSm26IHHzd4V{e2WmIHHzJIlv[2:{cH;yZZRqd25ib3[gX\|MzWF2DVGC=	MnqyNVg3Pjd\|MUK=
H1975	NWrKdHljU2mwYYPlJGF{e2G7	M{K2fFEh\|ryP	MWGyOEBp	M2CzVGROW09?	MYfkc4V{KG6xdDDpcohq[mm2IFXHSnIheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGgyQTd3IHPlcIx{KGijcnLvdolv\yCHR1\SJGw5PTiUL2S3PVBOKG23dHHueC=>	NIn5[W4zPDZyN{W5NS=>
H1975	NUS1b\|VoTnWwY4Tpc44hSXO\|YYm=	M4SxUlEh\|ryP	M{D4UlI1KGh?	M1\GV2ROW09?	NGS1e4Zld2W\|IH7veEBqdmirYnn0JGVTUyCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hUDF7N{WgZ4VtdHNiaHHyZo9zcW6pIFXHSnIhVDh3OGKvWFc6OE1?	MkHFNlQ3ODd3OUG=
HCC827	NIXNNmdMcW6jc3WgRZN{[Xl?	MnKyNE4yOSEQvF2=	NWruR\|lQOSCq	NX7BXnVzTE2VTx?=	NH;CZnJp[XNibn:gbZJz\X[ncoPpZoxmKGmwaHnibZRqd25ib3[gSWdHWiCjc4Pld5Nm\CCjczDy[YNwfmW{eTDv[kBGT0[UIHH1eI9xcG:\|cHjvdplt[XSrb36=	M1zBNVI1OTJ2OEm4
H1975	M1;NT2tqdmG\|ZTDBd5NigQ>?	M4n5clAvOzNizszN	MW[yJIg>	MVPEUXNQ	MUjkc4V{KG6xdDDpcohq[mm2IFXHSnIhVDh3OGKvWFc6OE1iZH;1ZoxmKG23dHHueEBie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gRWtVKHCqb4PwbI9zgWyjdHnvci=>	MoXpNlQyOjR6OUi=
H1975	M3\hdmtqdmG\|ZTDBd5NigQ>?	NWPGT\|BVOC5\|MzFOwG0>	NWPRcVZ5OiCq	NGTUb3VFVVOR	M3HrT4Rw\XNibn;0JIlvcGmkaYSgSWdHWiCOOEW4Vk9VPzlyTTDkc5VjdGVibYX0ZY51KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBGWkticHjvd5Bpd3K7bHH0bY9v	NILyOVIzPDF{NEi5PC=>
H1975	NVrw[ZJFU2mwYYPlJGF{e2G7	M2Ts[FAvOzNizszN	NXn0[INNOiCq	NWjwRmFWTE2VTx?=	MWTkc4V{KG6xdDDpcohq[mm2IFXHSnIhVDh3OGKvWFc6OE1iZH;1ZoxmKG23dHHueEBxcG:\|cHjvdplt[XSrb36=	NYjNXXBPOjRzMkS4PVg>
H1975	M1HJcmtqdmG\|ZTDBd5NigQ>?	MU[wMlEzPSEQvF2=	M4C3b\|I1KGh?	NUjYenJRTE2VTx?=	M2S3OYRw\XNibn;0JIlvcGmkaYSgSWdHWiCOOEW4Vk9VPzlyTTDteZRidnRiWUGwOlgh[XW2b4Doc5NxcG:{eXzheIlwdg>?	NHP2TmszOjN\|OUO0Ni=>
H1975	MV;LbY5ie2ViQYPzZZk>	MkC5NE42KM7:TR?=	NX\qcIFHOjRiaB?=	MorWSG1UVw>?	NGXWVJZld2W\|IH7veEBqdmirYnn0JGVITlJiTEi1PHIwXDd7MF2gcZV1[W62LX3l[IlifGWmIFXyb{BxcG:\|cHjvdplt[XSrb36=	MlrnNlI{Ozl\|NEK=
H1975	MYDLbY5ie2ViQYPzZZk>	MXewMlUh\|ryP	NFP0enUzPCCq	NFHNcpJFVVOR	NXi3cld7\G:nczDuc5QhcW6qaXLpeEBGT0[UIFy4OVhTN1R5OUDNJI12fGGwdD3t[YRq[XSnZDDBb5QheGixc4Doc5J6dGG2aX;u	NIixPIczOjN\|OUO0Ni=>
MIAPaCa2	NF3aO45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoXCNk42KM7:TR?=	MUO3NkBp	NXrCSolQTE2VTx?=	M4Tv[4hieyCwbzDndo94fGhiaX7obYJqfGmxbh?=	NIXo[VMzODR4NkW1OS=>
MIAPaCa2	MWXDfZRwfG:6aXOgRZN{[Xl?	MY[xJO69VQ>?	M331ZVExKGR?	Mkf2SG1UVw>?	NXrrV2hKcGG\|IH7vJIN6fG:2b4jpZ4l1gSCjc4Pld5Nm\CCjczDzeZBxemW\|c3nvckBw\iClb3zvcpkh\m:{bXH0bY9v	M2\DcVIxPDZ4NUW1
MIAPaCa2	NWfmO\|ljSXCxcITvd4l{KEG\|c3H5	NUjad5pjOTBizszN	M2K5TVI1cCCxcjC0PEBp	NGnnOVNFVVOR	M3TtT4Rw\XNibn;0JIlv\HWlZTDhdI9xfG:\|aYO=	MUOyNFQ3PjV3NR?=
MIAPaCa2	NFPqWmZCeG:ydH;zbZMhSXO\|YYm=	NVTESnlrOjBizszN	NEXuSm4zPCCq	NG\kb25FVVOR	MVTkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m\|IHHzd4V{e2WmIHHzJINie3Cjc3WgN{Bi[3SrdnH0bY9v	NFr0elczODR4NkW1OS=>
EoL-1	M1zDfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{exNGlEPTB;NT6xO{BvVQ>?	M1HMc3NCVkeHUh?=
NCI-H720	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTJ4LkmyJI5O	M1\HbnNCVkeHUh?=
NCI-SNU-5	NX\qb2hvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGnHUGlKSzVyPUK4MlE6KG6P	MWPTRW5ITVJ?
EW-3	NF3oTWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1znZmlEPTB;NE[uNFQhdk1?	MYPTRW5ITVJ?
HCC2218	NF7kZ\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTVyLkW5JI5O	M2fHcXNCVkeHUh?=
HuO-3N1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIjkTVBKSzVyPUW2MlA6KG6P	MWDTRW5ITVJ?
DB	M{jjN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1LGbWlEPTB;NkCuPVYhdk1?	MoriV2FPT0WU
HSC-4	Mnj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFGySmdKSzVyPU[xMlU{KG6P	MoG3V2FPT0WU
DOK	M3yzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmKzTWM2OD17Mz62NkBvVQ>?	NY\rfmt6W0GQR1XS
H9	MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTF\|Nz6yJI5O	NWHJNZYyW0GQR1XS
NCI-H292	Ml:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn7pTWM2OD1zNkKuOlYhdk1?	MUjTRW5ITVJ?
HSC-2	NXzW[HliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVzVTldNUUN3ME2xOlUvPTdibl2=	MX;TRW5ITVJ?
LU-65	M{TicWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MljtTWM2OD1zNk[uOlEhdk1?	MkL3V2FPT0WU
BV-173	NHXBXWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUO1TXIxUUN3ME2xPFYvPTVibl2=	NUjlPXZIW0GQR1XS
LB2241-RCC	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLIfJN{UUN3ME2xPVQvQTNibl2=	NWrtNHVWW0GQR1XS
KG-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4myTWlEPTB;MkC0MlM1KG6P	NX3SWFM2W0GQR1XS
CHL-1	NE[xcIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTJyOD61NUBvVQ>?	MX3TRW5ITVJ?
KYSE-140	NYO2R\|N1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWf5TFRQUUN3ME2yNFkvQTZibl2=	MmWwV2FPT0WU
DU-145	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTJzOT6wOEBvVQ>?	MV3TRW5ITVJ?
EW-13	NV7yZo9vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkHiTWM2OD1{MkWuNUBvVQ>?	M1TKc3NCVkeHUh?=
KYSE-450	NFrMZYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH3sRmZKSzVyPUK0O{46OiCwTR?=	M33n[HNCVkeHUh?=
CAL-72	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlnXTWM2OD1{NkiuO\|Mhdk1?	MUDTRW5ITVJ?
MEG-01	M17IbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTJ5Nj63OkBvVQ>?	MnjPV2FPT0WU
HCE-T	M{Phemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTJ5OT63PUBvVQ>?	M{jvdXNCVkeHUh?=
NCI-SNU-1	M4LQS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWLyOWs{UUN3ME2yPFMvOzJibl2=	MX;TRW5ITVJ?
CAL-27	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTJ6OT6wPEBvVQ>?	M{KwO3NCVkeHUh?=
BALL-1	NYjR[4NLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\oOW5KSzVyPUK5O{41OiCwTR?=	NHq4V3ZUSU6JRWK=
SBC-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFfaRW5KSzVyPUOwO{44QSCwTR?=	MoO3V2FPT0WU
CAL-54	M3r6N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnjaTWM2OD1\|MUGuNlMhdk1?	MlyzV2FPT0WU
TI-73	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NInERnRKSzVyPUOxNk44PSCwTR?=	MV3TRW5ITVJ?
P12-ICHIKAWA	M13hOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1HYUGlEPTB;M{K4MlA3KG6P	M{PLR3NCVkeHUh?=
ACHN	MnHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGnNNWVKSzVyPUOzNU41KG6P	M3q5SnNCVkeHUh?=
PC-14	MnHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NInKOllKSzVyPUOzN{41OSCwTR?=	MnztV2FPT0WU
HCC1806	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTN\|Nz61NUBvVQ>?	MmPlV2FPT0WU
SK-MEL-24	NGeyXXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jMTmlEPTB;M{O3Mlg4KG6P	NXHndI1{W0GQR1XS
A4-Fuk	M{P5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2DQdmlEPTB;M{WwMlAzKG6P	NUHVWlB{W0GQR1XS
ECC10	M4\nWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTN3Mj65OkBvVQ>?	NIfBb25USU6JRWK=
KASUMI-1	M4PtUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFyyd3NKSzVyPUO2Ok44OyCwTR?=	NVv5XHFEW0GQR1XS
CAL-33	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlyxTWM2OD1\|N{CuPUBvVQ>?	M{\1bHNCVkeHUh?=
MDA-MB-175-VII	M{fnb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTN5OD64PEBvVQ>?	NULXSXB6W0GQR1XS
NUGC-3	NUPnfmt4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn23TWM2OD12MEGuPFEhdk1?	NV;PUYpbW0GQR1XS
KY821	NILoXIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTRyOD61O{BvVQ>?	NISxdIxUSU6JRWK=
CTB-1	NH\rO3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnPlTWM2OD12MkSuOEBvVQ>?	NFS2T25USU6JRWK=
DoTc2-4510	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTR2Mj6xNkBvVQ>?	M4XUbHNCVkeHUh?=
EFO-27	NIfwOGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHK4dmxKSzVyPUS1OE44PCCwTR?=	NHX0e5ZUSU6JRWK=
BPH-1	M3vRcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnrcWZ6UUN3ME20PVEvOTZibl2=	M4HhdHNCVkeHUh?=
KYSE-270	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkjJTWM2OD12OUiuOlUhdk1?	Mn3VV2FPT0WU
HO-1-N-1	Mmj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTVyOT6yOUBvVQ>?	MYfTRW5ITVJ?
SK-MEL-1	NXLx[lBkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGPFTJhKSzVyPUWxNE46QSCwTR?=	NX;FRWt4W0GQR1XS
MOLT-13	NWnTcIRiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXLSR2VzUUN3ME21NVQvQDJibl2=	MYTTRW5ITVJ?
TK10	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUT4e5RRUUN3ME21NVUvOTFibl2=	MYDTRW5ITVJ?
HN	M3\ifmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTVzNz6zPEBvVQ>?	MmjRV2FPT0WU
SCC-15	NX3BToFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1nK[2lEPTB;NUK1MlY5KG6P	M1j6dXNCVkeHUh?=
NCI-H358	NILT[VdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFfQS4lKSzVyPUWyO{43PiCwTR?=	Ml7nV2FPT0WU
KYSE-180	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEDGPVdKSzVyPUWzNE43OiCwTR?=	NFTQcWpUSU6JRWK=
NCI-H82	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2jpVmlEPTB;NUSwMlUhdk1?	MkTZV2FPT0WU
NB7	NIO0UIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1nFWmlEPTB;NUS2MlMzKG6P	MWLTRW5ITVJ?
DSH1	NUjifFNST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTV4Nj64PEBvVQ>?	MV7TRW5ITVJ?
RS4-11	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX7n[VczUUN3ME21OlgvPTlibl2=	MXPTRW5ITVJ?
CAN	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoSyTWM2OD13OECuO\|Yhdk1?	NXLTS2VkW0GQR1XS
Ca9-22	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknuTWM2OD13OEiuOlQhdk1?	NXnSWnhTW0GQR1XS
CAL-39	MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVvqPYxIUUN3ME21PVYvOyCwTR?=	MonhV2FPT0WU
NCI-H1623	NVf3S5B6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XoPWlEPTB;NUm5MlM3KG6P	MnjmV2FPT0WU
FADU	M173Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nVTmlEPTB;NkC0MlY6KG6P	MVXTRW5ITVJ?
NB69	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTZzND6zOUBvVQ>?	MV\TRW5ITVJ?
Ramos-2G6-4C10	M4rMOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlXFTWM2OD14MkGuOFYhdk1?	MmfXV2FPT0WU
LB1047-RCC	M4TLPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmr5TWM2OD14MkWuNlkhdk1?	MX7TRW5ITVJ?
MV-4-11	NF3UUmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWXvT24zUUN3ME22NlcvPyCwTR?=	Mmj0V2FPT0WU
DBTRG-05MG	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTZ\|Mj6yPEBvVQ>?	M{juUXNCVkeHUh?=
ME-180	NH;Z[JNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkTqTWM2OD14M{KuPUBvVQ>?	M1rmbnNCVkeHUh?=
NBsusSR	NHjORZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTZ2Nj61NkBvVQ>?	M3\MZnNCVkeHUh?=
COR-L105	MnvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWT5eHlsUUN3ME22OlIvPTNibl2=	NFrhRmFUSU6JRWK=
ETK-1	M3O2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH7uc4tKSzVyPU[2Nk42QSCwTR?=	M4TnV3NCVkeHUh?=
L-363	M3jjZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;hT4tKSzVyPU[3NU46PCCwTR?=	NIXsXXNUSU6JRWK=
LU-134-A	NFvNRYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXnmOWtDUUN3ME23NVkvODlibl2=	MXPTRW5ITVJ?
NCI-H1770	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnDTWM2OD15MkKuOEBvVQ>?	NWjZO4RuW0GQR1XS
HAL-01	M3yy[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTd\|ND63NUBvVQ>?	MmflV2FPT0WU
COLO-684	NULkV4NXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTd3Mz6wNUBvVQ>?	NFzvV4JUSU6JRWK=
TE-6	NVnOUGE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEH2V4VKSzVyPUe2OE4{OSCwTR?=	MV7TRW5ITVJ?
A431	NIXaSVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYqyU3VZUUN3ME23PFAvODRibl2=	Mk\QV2FPT0WU
LU-135	NUXhZlViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmHQTWM2OD15OEOuNFMhdk1?	M2GydnNCVkeHUh?=
EC-GI-10	Mn7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYPzSmhMUUN3ME23PFgvPTJibl2=	NIPMeVRUSU6JRWK=
TE-12	M1jXbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTJR\|UxRTh{MT6xNUBvVQ>?	MnjsV2FPT0WU
LoVo	M{nzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLGfJZrUUN3ME24OVkvODZibl2=	MnG0V2FPT0WU
23132-87	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIPqOIFKSzVyPUi2OE4zQCCwTR?=	NIj5WVJUSU6JRWK=
AU565	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHvvclZKSzVyPUi2PU43KG6P	NHLCTohUSU6JRWK=
DEL	NYq2b4N1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTh5Nz62OUBvVQ>?	MUDTRW5ITVJ?
COR-L88	NEj1e4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHzPWI1KSzVyPUi4Nk4zPiCwTR?=	MnjXV2FPT0WU
NCI-H2126	MnOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTh6Mj64N{BvVQ>?	MoK5V2FPT0WU
CAPAN-1	M13OWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWfHUmtjUUN3ME24PFMvOjlibl2=	NU\WPY1XW0GQR1XS
BT-474	NWn6fWQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRTl\|OD6xOEBvVQ>?	M{HRdHNCVkeHUh?=
BHY	NW\s[oVyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXGzUYhSUUN3ME25O\|UvPDhibl2=	NHLJOnZUSU6JRWK=
HT-3	NWrk[HlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYDHOIp{UUN3ME25PFIvPDFibl2=	NFqwUZlUSU6JRWK=
SK-NEP-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGX0[m9KSzVyPUm4PU41PCCwTR?=	M2P3fXNCVkeHUh?=
MS-1	Mo\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVrRUmhGUUN3ME25PVQvPjlibl2=	Mom1V2FPT0WU
DOHH-2	NYO5Olh2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XiSGlEPTB;MT6wNFAzOSEQvF2=	NEH5e4RUSU6JRWK=
NCI-H1304	NUXqPWZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTFwMEG2OFMh\|ryP	MlTPV2FPT0WU
EM-2	NXfXbIx4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzFUnhKSzVyPUGuNFMxOTZizszN	NWnFUVQ6W0GQR1XS
MHH-PREB-1	MknSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3rTGE2UUN3ME2xMlA5PDVzIN88US=>	MoLMV2FPT0WU
KU-19-19	MoXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTFwMEi1OFEh\|ryP	M37YeHNCVkeHUh?=
NCI-H1648	M3njXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn3pTWM2OD1zLkGwOlE3KM7:TR?=	MX7TRW5ITVJ?
MKN1	MmL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoHlTWM2OD1zLkKxPVg4KM7:TR?=	M1e0VHNCVkeHUh?=
SNU-449	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYfPUWtMUUN3ME2xMlIzOjB6IN88US=>	M1X1enNCVkeHUh?=
OAW-42	MnfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn\wTWM2OD1zLkK3PFI2KM7:TR?=	NV:wWWRpW0GQR1XS
769-P	M4LZT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3vxO2lEPTB;MT6yO\|kyQCEQvF2=	NH;jWpFUSU6JRWK=
SW1088	NWPUfJBkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHTjVVBKSzVyPUGuNlk3ODdizszN	MnvQV2FPT0WU
GCIY	MlnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkPMTWM2OD1zLkOwNVMzKM7:TR?=	NEe3[XpUSU6JRWK=
CTV-1	NIfzdJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTFwM{C4JO69VQ>?	NEDje3dUSU6JRWK=
NCI-H1092	M4LKeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlX5TWM2OD1zLkOwPFUh\|ryP	NXHpXHp7W0GQR1XS
NKM-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFL5S\|RKSzVyPUGuN\|I2QTdizszN	NWHCOotkW0GQR1XS
NCI-H1650	NUTWT4Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTFwM{O0PFIh\|ryP	M1K1cnNCVkeHUh?=
SW954	M4\CT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXCNVNKSzVyPUGuN\|QxPDhizszN	NWrTfWExW0GQR1XS
SW48	Mo\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NILGSoxKSzVyPUGuN\|Y3OThizszN	NXWyOVBQW0GQR1XS
SK-N-DZ	NXTYbJVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTFwM{[5OFch\|ryP	NFi0b\|lUSU6JRWK=
KMOE-2	M33UPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlK1TWM2OD1zLkO5PFE2KM7:TR?=	NXrLVpFkW0GQR1XS
NB5	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1XrUGlEPTB;MT60NFg6PCEQvF2=	NE\LTVhUSU6JRWK=
CCRF-CEM	NY\uZlFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlXFTWM2OD1zLkSxNVEh\|ryP	M1LiOnNCVkeHUh?=
RH-1	MoHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkXHTWM2OD1zLkSxNVM3KM7:TR?=	Mn3UV2FPT0WU
NCI-H526	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTFwNEO4NlYh\|ryP	M17QRnNCVkeHUh?=
697	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTFwNESxNFQh\|ryP	MYXTRW5ITVJ?
J82	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTFwNEW3OlYh\|ryP	NXHqNYxHW0GQR1XS
BE-13	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHn4WIVKSzVyPUGuOVA3PzFizszN	MYDTRW5ITVJ?
SAS	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3v0ZmlEPTB;MT61NVYzOiEQvF2=	MVjTRW5ITVJ?
SCC-25	M1XSXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWjsOYNFUUN3ME2xMlUzOzJ{IN88US=>	MlTuV2FPT0WU
LAMA-84	MlfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYDtXZJiUUN3ME2xMlU{QDF3IN88US=>	MmPIV2FPT0WU
HSC-3	M4j2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRTFwNUSzPEDPxE1?	NH\hfnhUSU6JRWK=
BT-549	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUnHVXhiUUN3ME2xMlU5PzR5IN88US=>	MU\TRW5ITVJ?
ML-2	NEXCfW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M16wbGlEPTB;MT62OFAzQSEQvF2=	NH\JRmlUSU6JRWK=
BB30-HNC	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTFwNki5O\|Ih\|ryP	MWnTRW5ITVJ?
PANC-03-27	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTFwN{CxN\|kh\|ryP	M1TnZXNCVkeHUh?=
COLO-678	MlTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M32wWWlEPTB;MT63N\|Q1PCEQvF2=	M4\UTXNCVkeHUh?=
NCI-H1666	NXGye2tGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn32TWM2OD1zLke0O\|A1KM7:TR?=	M{LEdHNCVkeHUh?=
NCI-H209	NYHaW417T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkLYTWM2OD1zLke3NlY6KM7:TR?=	NYrUNngzW0GQR1XS
EPLC-272H	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTFwOEW1OFkh\|ryP	MX7TRW5ITVJ?
OMC-1	M2j6Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTFwOUm4PFgh\|ryP	NX3EVlMxW0GQR1XS
HCC70	NITJc4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTJwMEC4NVUh\|ryP	MX7TRW5ITVJ?
CAL-12T	M1HSRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX31d2J1UUN3ME2yMlAyQDZzIN88US=>	NEjqc3VUSU6JRWK=
TGBC24TKB	NFrWbpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH7GNIRKSzVyPUKuNFI6PjFizszN	Mln4V2FPT0WU
EKVX	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYX6eop2UUN3ME2yMlA1QTN7IN88US=>	MkXTV2FPT0WU
SW1116	NGCzVoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlm5TWM2OD1{LkC2NFA6KM7:TR?=	MXnTRW5ITVJ?
NCI-H2009	NH\KdmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTJwME[yNVQh\|ryP	MUHTRW5ITVJ?
RPMI-8866	M1LlR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHvTZYFKSzVyPUKuNFg1QDFizszN	M2DhU3NCVkeHUh?=
KARPAS-45	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTJwMUK0O\|kh\|ryP	M4\sXXNCVkeHUh?=
RXF393	MmDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTJwMUOwN\|Yh\|ryP	M{TOc3NCVkeHUh?=
786-0	NV7OOlhpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\3eWlEPTB;Mj6xPFQxPiEQvF2=	MUPTRW5ITVJ?
SCC-4	NFPuVmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4fzZmlEPTB;Mj6yNVc4PiEQvF2=	MVrTRW5ITVJ?
BT-20	M2XJXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTJwMk[3OFQh\|ryP	MXPTRW5ITVJ?
A498	NELtOplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\5TWM2OD1{LkK5OFE2KM7:TR?=	MVfTRW5ITVJ?
IGROV-1	NX:1enVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTJwM{GyN\|ch\|ryP	MmX4V2FPT0WU
JVM-3	M1zUSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHP6PWhKSzVyPUKuN\|Q3PDNizszN	NFHofIFUSU6JRWK=
NCI-H2170	NVzEfItnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnsRW1IUUN3ME2yMlM1Pzh\|IN88US=>	MXvTRW5ITVJ?
EW-18	M1X3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jEdmlEPTB;Mj6zOVQ4OSEQvF2=	M2LSenNCVkeHUh?=
KU812	NFOzWYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTJwM{[3O\|kh\|ryP	Ml;lV2FPT0WU
NY	M3TKWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEHQT4tKSzVyPUKuN\|czPyEQvF2=	NWSwbmZRW0GQR1XS
HTC-C3	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIj6SmJKSzVyPUKuOFIzPjdizszN	MVnTRW5ITVJ?
CFPAC-1	NV;CSI55T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmHQTWM2OD1{LkSzPFY1KM7:TR?=	NFnhcFBUSU6JRWK=
HH	MmPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LCNGlEPTB;Mj60PVg2PCEQvF2=	MnjOV2FPT0WU
MKN7	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPTTWM2OD1{Lk[yO\|Q5KM7:TR?=	MUXTRW5ITVJ?
TE-8	MoLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkTETWM2OD1{Lk[zOlU{KM7:TR?=	NVv6VodFW0GQR1XS
MC-IXC	M{DGPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\YTWM2OD1{Lk[0OFU{KM7:TR?=	M2D1WHNCVkeHUh?=
DMS-79	NUG5S5ZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1H1VmlEPTB;Mj62PVI5PCEQvF2=	M37ienNCVkeHUh?=
Detroit562	MnfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTJwNkm4OFUh\|ryP	NGXnW4RUSU6JRWK=
HuP-T4	Moe1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknsTWM2OD1{LkeyPFE5KM7:TR?=	MkfzV2FPT0WU
QIMR-WIL	M{XyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mk[2TWM2OD1{Lke1PVUzKM7:TR?=	NFvYZ29USU6JRWK=
BB65-RCC	MlLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTJwOEC3NVMh\|ryP	MkfoV2FPT0WU
PC-3	NWP5RnU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2XsdmlEPTB;Mj64N\|MyPyEQvF2=	MYfTRW5ITVJ?
OVCAR-3	M3vQcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTJwOEW1PVQh\|ryP	Ml[5V2FPT0WU
KYSE-510	M{T3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LSe2lEPTB;Mj64Olc5PiEQvF2=	NGq1d3pUSU6JRWK=
HC-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTJwOUSwNVIh\|ryP	NX62dFJoW0GQR1XS
NCI-H1693	NF3MbFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Moj0TWM2OD1{Lkm1PFk4KM7:TR?=	NYHwZotUW0GQR1XS
DU-4475	NH22do1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13nXGlEPTB;Mj65PVA2OiEQvF2=	MmHjV2FPT0WU
COLO-680N	NGfFWGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGfBZpVKSzVyPUOuNFA1QTVizszN	NGLXfXdUSU6JRWK=
MN-60	M17ORmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlPsTWM2OD1\|LkC0PVc1KM7:TR?=	NXzlSYpbW0GQR1XS
BCPAP	MmjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mkf3TWM2OD1\|LkC4Nlk2KM7:TR?=	M{nlcXNCVkeHUh?=
647-V	NH7ifYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1q5eWlEPTB;Mz6xOlIzKM7:TR?=	NVXjfoExW0GQR1XS
HT-1376	M2HKemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXnVGx4UUN3ME2zMlIxPTB4IN88US=>	M16xXXNCVkeHUh?=
NCI-H1793	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY\YboI{UUN3ME2zMlIyODl6IN88US=>	Mme2V2FPT0WU
SW1463	Mk\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2jkTWlEPTB;Mz6yOlE6OiEQvF2=	MYLTRW5ITVJ?
NCI-H727	MonaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jXZ2lEPTB;Mz6zPFU5PCEQvF2=	NFS4TY9USU6JRWK=
LB771-HNC	NHPPN49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTNwM{mxNlYh\|ryP	NVP5VIwzW0GQR1XS
D-542MG	Mm\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTNwNESyNlIh\|ryP	MWrTRW5ITVJ?
NTERA-S-cl-D1	M{jZSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTNwNES5OVch\|ryP	MortV2FPT0WU
C8166	M4q1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoXXTWM2OD1\|LkS2OVIyKM7:TR?=	MY\TRW5ITVJ?
639-V	NUn5RVZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MknnTWM2OD1\|LkW3O\|kzKM7:TR?=	MXrTRW5ITVJ?
TE-1	M2HjTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{i0fmlEPTB;Mz61PVE3QSEQvF2=	MmfnV2FPT0WU
OAW-28	M{PCOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3fYfWlEPTB;Mz61PVQzPiEQvF2=	MVXTRW5ITVJ?
SK-LU-1	NGHYcHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVrHXlBkUUN3ME2zMlYxPjR3IN88US=>	MX;TRW5ITVJ?
CaR-1	NWOyW\|BzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVnuRZZGUUN3ME2zMlYyODR6IN88US=>	NYnPcXNHW0GQR1XS
A2780	M{LsZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnfMTWM2OD1\|Lk[0NFg6KM7:TR?=	M1ezPXNCVkeHUh?=
C2BBe1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\zTWM2OD1\|Lk[0OFA4KM7:TR?=	Mnn5V2FPT0WU
SK-MES-1	NWXve3hGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkTOTWM2OD1\|Lk[0OlE1KM7:TR?=	NVf0VGNtW0GQR1XS
PANC-10-05	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXzJR\|UxRTNwN{KwO\|Ih\|ryP	M1P1[nNCVkeHUh?=
J-RT3-T3-5	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX32[HNwUUN3ME2zMlc2PDB4IN88US=>	MXHTRW5ITVJ?
ES4	NYj3Zmp3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4C4R2lEPTB;Mz64NlI5PiEQvF2=	M{TxWnNCVkeHUh?=
NCI-H28	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXzlTpVKUUN3ME2zMlgzQTZzIN88US=>	NUewPIJ{W0GQR1XS
NCI-H1155	NF7wb21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1TxZ2lEPTB;Mz64OFE2QSEQvF2=	MojDV2FPT0WU
KURAMOCHI	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkO1TWM2OD1\|Lki2NFU3KM7:TR?=	MVfTRW5ITVJ?
NCI-H69	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYfJR\|UxRTNwOUCxO\|gh\|ryP	MWHTRW5ITVJ?
IST-MES1	M4XMR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXTHPYRbUUN3ME2zMlk1ODJ7IN88US=>	Ml;2V2FPT0WU
NH-12	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M13y[2lEPTB;Mz65OFE5PyEQvF2=	M2f0SnNCVkeHUh?=
JVM-2	NX\uZ5VUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI\2U4JKSzVyPUOuPVQ4PTJizszN	NXz2RpBWW0GQR1XS
EW-16	NUTlcWM4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\zTWM2OD1\|Lkm1OVc4KM7:TR?=	Mkm0V2FPT0WU
NCI-H441	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3LtTmlEPTB;Mz65O\|AyPCEQvF2=	MYrTRW5ITVJ?
RCC10RGB	M3THSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIDuVINKSzVyPUSuNFEzPDZizszN	M2TDZ3NCVkeHUh?=
TCCSUP	MmXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nyWGlEPTB;ND6xNVA2KM7:TR?=	MnTVV2FPT0WU
HL-60	NV3LVJB{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;wSGlEPTB;ND6xNlI1OSEQvF2=	NX[0O41bW0GQR1XS
EW-11	NHvyUXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEj6UVZKSzVyPUSuNVMzPjFizszN	NEXnV5hUSU6JRWK=
KARPAS-299	NIq3VFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\LTWM2OD12LkOxNFE{KM7:TR?=	MXfTRW5ITVJ?
SNU-C2B	M37yUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTRwM{S2PFYh\|ryP	Ml63V2FPT0WU
LU-139	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2nF[WlEPTB;ND6zO\|I1PyEQvF2=	MXXTRW5ITVJ?
HCC1937	M3i4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnrITWM2OD12LkO3PVk{KM7:TR?=	MXnTRW5ITVJ?
GR-ST	MofVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlHRTWM2OD12LkSzNVgh\|ryP	MWrTRW5ITVJ?
SK-OV-3	M13UZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTRwNE[wOFIh\|ryP	MmTmV2FPT0WU
A172	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTRwNUW1NlEh\|ryP	NFPuUXJUSU6JRWK=
NB10	MoDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYjsWXRqUUN3ME20MlU6PzhzIN88US=>	NFrRdJlUSU6JRWK=
P30-OHK	NHmyc4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfRVldKSzVyPUSuPFE6OjlizszN	NVH5NnBmW0GQR1XS
KYSE-520	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTRwOEiwNVgh\|ryP	M4\USHNCVkeHUh?=
KNS-62	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXGw[4tXUUN3ME20MlkxQDB5IN88US=>	NV;kZ5hNW0GQR1XS
ES1	NEnKfJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4n4NmlEPTB;ND65OlA{PSEQvF2=	NHKzdFRUSU6JRWK=
KOSC-2	MmC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlLhTWM2OD12Lkm5PVU6KM7:TR?=	NH3abIVUSU6JRWK=
TE-9	MmW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml74TWM2OD13LkCxOVI2KM7:TR?=	NXqyWZdYW0GQR1XS
NCI-H1838	NVzSe3NbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2nNO2lEPTB;NT6wNlA4PiEQvF2=	NGjiOYRUSU6JRWK=
KP-N-YN	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTVwMUK1PVEh\|ryP	MnHCV2FPT0WU
ALL-PO	M4XKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnyPWZKSzVyPUWuNlI2QDdizszN	MlnBV2FPT0WU
NOMO-1	M1jvfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;aTWM2OD13LkKzNVc3KM7:TR?=	MVfTRW5ITVJ?
CGTH-W-1	Ml3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTVwM{i1PFQh\|ryP	NGDBUmNUSU6JRWK=
ATN-1	M3r4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M13FemlEPTB;NT60NVE5PCEQvF2=	NYHZRm5RW0GQR1XS
AGS	NFuwNVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3y5U2lEPTB;NT60PVYyQCEQvF2=	MkXwV2FPT0WU
SW13	MoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmP4TWM2OD13LkWzNlY2KM7:TR?=	NWXudHB6W0GQR1XS
SW1990	NYTGfoE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjXW\|hKSzVyPUWuOlIzQDVizszN	NFnLclZUSU6JRWK=
BFTC-905	M{S5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGf2dVZKSzVyPUWuOlU5PzhizszN	MWnTRW5ITVJ?
RMG-I	M{jUcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml7VTWM2OD13Lk[1PVQzKM7:TR?=	NFfhR41USU6JRWK=
HD-MY-Z	NIfINo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH32dGtKSzVyPUWuOlg2QDFizszN	NHiy[2RUSU6JRWK=
HCC1187	NHrZPY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnCSW9KUUN3ME21MlcyODN{IN88US=>	MmraV2FPT0WU
HCC2998	M{DTdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTVwN{G4O\|ch\|ryP	NX7PNoJKW0GQR1XS
RT-112	NUC1cHBiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlT5TWM2OD13LkmwNlQ2KM7:TR?=	NEnofmNUSU6JRWK=
CAKI-1	M4\mOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYLkcng{UUN3ME22MlAxQTh3IN88US=>	M1y1WnNCVkeHUh?=
HDLM-2	Ml7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXvFWm1ZUUN3ME22MlAyPDh7IN88US=>	MlXLV2FPT0WU
TE-10	NIW0VldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHPz[5ZKSzVyPU[uNFQ5OzNizszN	M{HNWXNCVkeHUh?=
KE-37	M4\ES2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXPBbFNNUUN3ME22MlA4OjV6IN88US=>	MnzzV2FPT0WU
RCM-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTZwMEe3NVkh\|ryP	NFP6ZW5USU6JRWK=
Mewo	NGqyWoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTZwMUG0PFch\|ryP	M1rlbXNCVkeHUh?=
L-428	NWXXdo8{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTZwMUiwN\|ch\|ryP	NHLuU4VUSU6JRWK=
8-MG-BA	NVrxVopZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33FeWlEPTB;Nj6xPVM4QSEQvF2=	NET4d3NUSU6JRWK=
SK-MEL-28	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTZwMkC5Olch\|ryP	Ml:zV2FPT0WU
VA-ES-BJ	NX;5SYRjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTZwM{C0OlIh\|ryP	MUfTRW5ITVJ?
CAL-120	MnSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIK3TVhKSzVyPU[uOFUyPjJizszN	MYTTRW5ITVJ?
GAMG	MoHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2D5dGlEPTB;Nj61NFYzKM7:TR?=	NF;RNYdUSU6JRWK=
MSTO-221H	NHTZeolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDNTWM2OD14LkWxNVch\|ryP	MWPTRW5ITVJ?
GCT	MkftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTZwNUOzPFch\|ryP	NH;DUldUSU6JRWK=
SH-4	NVXYdWg4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2mw[2lEPTB;Nj61PFg1PCEQvF2=	MV3TRW5ITVJ?
Calu-3	NIDqSVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnhTWM2OD14Lk[1OVY5KM7:TR?=	NEXse2tUSU6JRWK=
SK-HEP-1	NWPZVJFGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoG0TWM2OD14LkexO\|U{KM7:TR?=	NFTvWmNUSU6JRWK=
PFSK-1	NI\1dXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTZwN{O0O\|gh\|ryP	Ml70V2FPT0WU
NB12	MmLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXjvVWx4UUN3ME22Mlc5PDB2IN88US=>	MYnTRW5ITVJ?
A388	NY\kbIlDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYDUfpo4UUN3ME22Mlg6PTJizszN	MnLJV2FPT0WU
KLE	NGjuZ3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmHtTWM2OD14Lkm2OVE3KM7:TR?=	M3rUVnNCVkeHUh?=
TE-11	NGK5RYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTdwMES5Olch\|ryP	NIrGN4RUSU6JRWK=
NCI-H2405	NVLWO5MyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoLhTWM2OD15LkC4N\|k{KM7:TR?=	M3Hq[HNCVkeHUh?=
OVCAR-4	NVH1WHZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlS5TWM2OD15LkG1N\|Uh\|ryP	NUDWe4k{W0GQR1XS
KP-N-YS	NF3T[\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWLKc2tnUUN3ME23MlE5OTRizszN	M3;YV3NCVkeHUh?=
NOS-1	NFLNZ3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmLsTWM2OD15LkK1PFI5KM7:TR?=	NH\iWFBUSU6JRWK=
DMS-114	NYS4N3NXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTdwMkm2N\|Eh\|ryP	MkTYV2FPT0WU
NCI-H2030	NEOzTpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIO1cVdKSzVyPUeuN\|M3QThizszN	M4fPSnNCVkeHUh?=
HEL	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXnQZ\|M1UUN3ME23MlM4PTJzIN88US=>	NWTlOJBZW0GQR1XS
CAL-62	NX[2cm0yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjTR\|llUUN3ME23MlM6QDZ4IN88US=>	NFHhS41USU6JRWK=
COLO-668	M{fIcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEL0[5BKSzVyPUeuOFM6PjdizszN	M{WxNXNCVkeHUh?=
SKG-IIIa	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnPsTWM2OD15LkS1N\|gyKM7:TR?=	M1vwUXNCVkeHUh?=
HCC1419	Ml[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4S4UmlEPTB;Nz60Olg{OyEQvF2=	MYDTRW5ITVJ?
OS-RC-2	M2iwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHTDdlhKSzVyPUeuOFk5QTRizszN	M3\WTHNCVkeHUh?=
COLO-829	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn73TWM2OD15Lk[2OFY{KM7:TR?=	MYLTRW5ITVJ?
NB13	NHrWVlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmHBTWM2OD15LkiyOlY4KM7:TR?=	MoLLV2FPT0WU
DK-MG	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYLXfGx2UUN3ME23Mlg{OjBzIN88US=>	MW\TRW5ITVJ?
SHP-77	NH3qe41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoP5TWM2OD15Lki2OlU{KM7:TR?=	NH76RplUSU6JRWK=
NCI-H661	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRThwMEW4Olch\|ryP	NHO2N5RUSU6JRWK=
AM-38	M2nCZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRThwMU[yPEDPxE1?	NFPZPFVUSU6JRWK=
VM-CUB-1	M2exTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;CTWM2OD16LkG3NFI6KM7:TR?=	M1L0eHNCVkeHUh?=
KYSE-70	M1nuU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRThwMUm3OlEh\|ryP	Moi5V2FPT0WU
5637	NHzhU4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEXqS\|RKSzVyPUiuN\|ExPTVizszN	MmnqV2FPT0WU
TGBC11TKB	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2[4PWlEPTB;OD60OlE3PCEQvF2=	M4D5fHNCVkeHUh?=
EGI-1	NUTnNY9jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH3lOnlKSzVyPUiuOlAxQDhizszN	M{iwNHNCVkeHUh?=
D-392MG	NUn3XXNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmnVTWM2OD16Lk[2NlE1KM7:TR?=	MVfTRW5ITVJ?
A673	MoixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3MXXRKSzVyPUiuOlc3OTFizszN	NVi0TIJPW0GQR1XS
COLO-792	MkDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFrrWW1KSzVyPUiuO\|Q6PDZizszN	M3H4ZXNCVkeHUh?=
NCI-H1792	NYPRPYl6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDaOoFKSzVyPUiuPFg6ODNizszN	MYXTRW5ITVJ?
LS-1034	NX;WSXpOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkHyTWM2OD16Lkm0OlUzKM7:TR?=	NEXrWlZUSU6JRWK=
D-566MG	NVPnT404T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTlwMEG4NUDPxE1?	MUDTRW5ITVJ?
NCI-H226	NEO2RVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlzBTWM2OD17LkC5JO69VQ>?	Mn[yV2FPT0WU
ChaGo-K-1	NEPRSnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1j2WmlEPTB;OT6xNFU4QSEQvF2=	NXPwbnJZW0GQR1XS
NCI-H2228	NYnYeG92T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnjWTWM2OD17LkGxNFgyKM7:TR?=	NHXSfo1USU6JRWK=
RPMI-8226	M1\MZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmi1TWM2OD17LkGxN\|A1KM7:TR?=	MnHQV2FPT0WU
BFTC-909	NV;ZUVZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUfOfXpqUUN3ME25MlE5Ojl5IN88US=>	NVvwRYFnW0GQR1XS
HPAF-II	MojVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRTlwMkK1NVgh\|ryP	M{XGTXNCVkeHUh?=
Capan-2	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3f0eWlEPTB;OT60NFExQSEQvF2=	NXXXc5hPW0GQR1XS
IA-LM	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1jnSWlEPTB;OT60NVk3PiEQvF2=	MlzDV2FPT0WU
KP-4	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH7KS4ZKSzVyPUmuOFg5OzhizszN	MV\TRW5ITVJ?
A101D	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlTjTWM2OD17LkWxO\|E6KM7:TR?=	M{S0PXNCVkeHUh?=
EFO-21	MlLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHLTWM2OD17LkW4O\|M2KM7:TR?=	M{ftd3NCVkeHUh?=
C32	MmTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLZTWM2OD17Lk[zN\|Qh\|ryP	MoTRV2FPT0WU
SW837	NFrmSWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVrBZ4lNUUN3ME25Mlg1QDJizszN	NVfwXXMyW0GQR1XS
OCI-AML2	NEPiToxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTlwOE[5OkDPxE1?	NV3nSItNW0GQR1XS
NCI-H1355	M1PFV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rrZmlEPTB;OT65OFA5QCEQvF2=	NIPqPHpUSU6JRWK=
NCI-H2342	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXHObnhwUUN3ME2xNE4xOTV3IN88US=>	M1HrdnNCVkeHUh?=
A204	NHLGTZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTFyLkC0OlYh\|ryP	NXrie5dGW0GQR1XS
CAL-51	MnTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NETTVIVKSzVyPUGwMlA5PzdizszN	MXPTRW5ITVJ?
HCE-4	Mm\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkDWTWM2OD1zMD6xNVIzKM7:TR?=	NV;I[YhiW0GQR1XS
NCI-H810	NXrUZpRzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDTTWM2OD1zMD6xOVk4KM7:TR?=	NVrLcm51W0GQR1XS
DJM-1	NWjURYpGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NITmZWlKSzVyPUGwMlE4OzJizszN	NFeybndUSU6JRWK=
SK-UT-1	NGTJVIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHu3b\|FKSzVyPUGwMlI2PzRizszN	NFLtd49USU6JRWK=
U031	NFfsbHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1rCN2lEPTB;MUCuNlY5PiEQvF2=	NX;WS5hQW0GQR1XS
YH-13	NFXBdVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTFyLkOwOVch\|ryP	NWLiSXlnW0GQR1XS
K5	NUPadlkxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUfGO2oxUUN3ME2xNE4{Ozl3IN88US=>	MoDyV2FPT0WU
HEC-1	M{PVUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnizTWM2OD1zMD60NFgyKM7:TR?=	MlH0V2FPT0WU
A2058	NHrsfoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlS5TWM2OD1zMD61OFkyKM7:TR?=	NWfHeIFGW0GQR1XS
SW962	MnXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTFyLk[yNFQh\|ryP	MXXTRW5ITVJ?
VMRC-RCZ	MlLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTFyLk[3OFkh\|ryP	NFrHNG9USU6JRWK=
D-336MG	NGLZPHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmHhTWM2OD1zMD63NFA2KM7:TR?=	MWrTRW5ITVJ?
LXF-289	MlfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{D1dGlEPTB;MUCuO\|k3PyEQvF2=	M{jWTHNCVkeHUh?=
SW900	Mn35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{THRWlEPTB;MUCuPFIzQCEQvF2=	NEH6d4ZUSU6JRWK=
K-562	NFuzdFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13ZPWlEPTB;MUCuPFM6PSEQvF2=	MYrTRW5ITVJ?
HCC38	NHHKb\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmWyTWM2OD1zMD65O\|E3KM7:TR?=	M4\HVnNCVkeHUh?=
SF-295	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXrM[IxmUUN3ME2xNE46QTB{IN88US=>	MWDTRW5ITVJ?
LB831-BLC	NETNVXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfMTWM2OD1zMT6yOVU3KM7:TR?=	MmrrV2FPT0WU
FTC-133	NXz2T5dvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn7ITWM2OD1zMT6zNFgyKM7:TR?=	MnruV2FPT0WU
HCC1954	NV60bFZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEnkfmdKSzVyPUGxMlQ{PiEQvF2=	NVviSnppW0GQR1XS
GOTO	NVXNNWVvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYnX[m94UUN3ME2xNU42OjB4IN88US=>	NH73d2JUSU6JRWK=
LS-411N	NUHBfGVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1v2b2lEPTB;MUGuOlExOSEQvF2=	MYDTRW5ITVJ?
RPMI-7951	NEHITHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTFzLk[zOFgh\|ryP	NXrYXWdoW0GQR1XS
NCI-H1299	MkTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFjn[4JKSzVyPUGxMlY3PDdizszN	MU\TRW5ITVJ?
MLMA	NWjLSWw{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHVUVZKSzVyPUGxMlY6QTdizszN	MkTVV2FPT0WU
MMAC-SF	M3vsU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;xWWlEPTB;MUGuO\|I2OiEQvF2=	NF3pdlRUSU6JRWK=
UM-UC-3	Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHjHNm9KSzVyPUGxMlc1OjFizszN	MnXOV2FPT0WU
SCC-9	M4rTS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTFzLkixOVEh\|ryP	NFnRWmVUSU6JRWK=
HOS	M4HINGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV;NTJNmUUN3ME2xNU45Pjh\|IN88US=>	NW\2bVF6W0GQR1XS
OE19	MlTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;Cb\|l{UUN3ME2xNU46OzZ5IN88US=>	NFzVNXdUSU6JRWK=
Mo-T	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTFzLkm1OFEh\|ryP	NHL0V\|hUSU6JRWK=
CAMA-1	M363eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTF{LkG2N\|Mh\|ryP	NIjDdlhUSU6JRWK=
U-118-MG	MljJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYPCXFFYUUN3ME2xNk4zPDRzIN88US=>	MnP3V2FPT0WU
KS-1	M1PaVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTJR\|UxRTF{LkK4N\|Ih\|ryP	MlnDV2FPT0WU
JAR	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGeycI1KSzVyPUGyMlM{PjlizszN	NH34ZmFUSU6JRWK=
ABC-1	Mlq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIPKfFJKSzVyPUGyMlM1OSEQvF2=	NXnZdldpW0GQR1XS
Daoy	NU\NcoF6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYHLZo5RUUN3ME2xNk41PTR{IN88US=>	NYDaXVZxW0GQR1XS
C3A	NFPFeWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYW1XIQ{UUN3ME2xNk42Pzh3IN88US=>	M{HBfXNCVkeHUh?=
GT3TKB	Mn7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFXOVm5KSzVyPUGyMlY{OjdizszN	MoDNV2FPT0WU
DMS-273	M3zYe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1TBU2lEPTB;MUKuPFY{OyEQvF2=	NELGZ3NUSU6JRWK=
G-361	NILaelVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTF{LkmxNlkh\|ryP	Mkf2V2FPT0WU
RH-18	NIXDcYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\OWFJKSzVyPUGzMlI6PjJizszN	NV\EbndyW0GQR1XS
SN12C	NEDVT2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2fncGlEPTB;MUOuN\|gxQCEQvF2=	MmnwV2FPT0WU
NCI-H1993	M{ToV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{HWdmlEPTB;MUOuOFI5PSEQvF2=	M2XMfnNCVkeHUh?=
LOXIMVI	NELVSGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmD3TWM2OD1zMz62NVUyKM7:TR?=	MUTTRW5ITVJ?
SK-PN-DW	MlnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2\1TGlEPTB;MUOuPFQzPyEQvF2=	MoSwV2FPT0WU
KALS-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVvrWmU6UUN3ME2xN{45PTJ3IN88US=>	MYPTRW5ITVJ?
LAN-6	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILPcXRKSzVyPUG0MlI2OyEQvF2=	NVnUW5NTW0GQR1XS
A549	NEDHdmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULKVlhIUUN3ME2xOE41PzF{IN88US=>	MUTTRW5ITVJ?
RD	NWrQPGNmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH3LdZFKSzVyPUG0MlQ5OTNizszN	NVLvZYRzW0GQR1XS
TGBC1TKB	NVXFeXZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTF2Lk[2NVUh\|ryP	NWnJTpBuW0GQR1XS
NCI-H630	M1P6cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1Xr[WlEPTB;MUSuPVQ3PyEQvF2=	NVXLbI9OW0GQR1XS
MIA-PaCa-2	NFr5fYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTF2Lkm2PUDPxE1?	M{DUfnNCVkeHUh?=
NCI-H1755	M33xcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3riPWlEPTB;MUSuPVk2OyEQvF2=	NGjHd\|NUSU6JRWK=
MOLT-4	NXfoSHlFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV7w[\|U4UUN3ME2xOU4xPDl5IN88US=>	NWjtO\|Q5W0GQR1XS
CW-2	NUfhWJAzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUf3dWRoUUN3ME2xOU4yPDJzIN88US=>	NHnQVotUSU6JRWK=
COLO-320-HSR	MknXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUO3S5JzUUN3ME2xOU42OzB5IN88US=>	NIDmRYtUSU6JRWK=
UMC-11	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTF3Lke1NlMh\|ryP	M{G0Z3NCVkeHUh?=
MCF7	NIfoXFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTF3LkixOFUh\|ryP	NEnjPJpUSU6JRWK=
NCI-H23	MnHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFWzO3hKSzVyPUG1Mlg1OzhizszN	NV3yOW1rW0GQR1XS
HuCCT1	M{nNe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;xTWM2OD1zNT64O\|Qh\|ryP	MWXTRW5ITVJ?
MPP-89	NYnKZoFMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUi3bmlLUUN3ME2xOU46PDF5IN88US=>	M4TjZnNCVkeHUh?=
HT55	M1u1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTF3Lkm0O\|gh\|ryP	NFjacmVUSU6JRWK=
no-11	NGWybHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoSxTWM2OD1zNT65OlY{KM7:TR?=	NH:1SotUSU6JRWK=
GP5d	NUfBbFNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2PiOmlEPTB;MU[uNlE5PyEQvF2=	MXzTRW5ITVJ?
BHT-101	NIC0Z45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MofITWM2OD1zNj6yOFM6KM7:TR?=	M3PzUHNCVkeHUh?=
M059J	NGnlWHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4nlO2lEPTB;MU[uNlg1KM7:TR?=	M3[ycHNCVkeHUh?=
D-283MED	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWn5d5RMUUN3ME2xOk41OjB7IN88US=>	MUHTRW5ITVJ?
BEN	NUe3PVAzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmW2TWM2OD1zNj61NVU2KM7:TR?=	NInrV3lUSU6JRWK=
LB373-MEL-D	NWHXXmJnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn;tTWM2OD1zNj63NlMzKM7:TR?=	M1n4S3NCVkeHUh?=
MEL-HO	NF7T[JpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTF4Lki4OVQh\|ryP	MX\TRW5ITVJ?
GI-ME-N	NF24XWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3zEUmlEPTB;MU[uPVA{OiEQvF2=	NIeyUYFUSU6JRWK=
RKO	M2C4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4jvO2lEPTB;MUeuNFc1QCEQvF2=	NFzXTWJUSU6JRWK=
MZ2-MEL	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGXuS\|lKSzVyPUG3MlE{OyEQvF2=	MlThV2FPT0WU
NCI-H1573	NYHlSIdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1TQdmlEPTB;MUeuNlgzPiEQvF2=	M2XnNXNCVkeHUh?=
NCI-H1581	MkLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnBbIZKSzVyPUG3MlQ1OTFizszN	NF63S4xUSU6JRWK=
NCI-H747	NHXQe4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV31O4dPUUN3ME2xO{42Ojl5IN88US=>	Mom3V2FPT0WU
SW1783	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUnW[I9iUUN3ME2xO{43PDF3IN88US=>	NE\M[mZUSU6JRWK=
Calu-6	Mn2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4TOUmlEPTB;MUeuOlc5OiEQvF2=	MVnTRW5ITVJ?
SF268	NVHvclBvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFv6WJRKSzVyPUG3MlY6PjlizszN	MnXKV2FPT0WU
ES8	NG\lVJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTF5Lki1PVMh\|ryP	MX\TRW5ITVJ?
KM-H2	NVnjUHBpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGHRe4xKSzVyPUG3Mlk1OTFizszN	NIS2WmRUSU6JRWK=
D-502MG	MoTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkfPTWM2OD1zNz65PFA5KM7:TR?=	NID4SWpUSU6JRWK=
HLE	M1vGcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3j4ZWlEPTB;MUiuN\|E1QCEQvF2=	MmPlV2FPT0WU
SW982	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoC2TWM2OD1zOD60NFc2KM7:TR?=	NVvBNoJQW0GQR1XS
MDA-MB-361	NUGyUlN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTF6LkW1PFgh\|ryP	NH\3fo5USU6JRWK=
NCI-H1563	NGHNSFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\1W5hKSzVyPUG4MlcyOjRizszN	M2r4XHNCVkeHUh?=
MFE-280	Mo\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{XFUWlEPTB;MUiuO\|I6OyEQvF2=	NWK5bHJMW0GQR1XS
U251	NYTmdXJoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\ISGlEPTB;MUiuO\|M1PyEQvF2=	M2i2e3NCVkeHUh?=
KNS-42	M3:1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYrKcVl2UUN3ME2xPE45ODF3IN88US=>	M3fUPXNCVkeHUh?=
U-266	MmP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofBTWM2OD1zOD64OlQ6KM7:TR?=	Mny1V2FPT0WU
OVCAR-8	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1vkPWlEPTB;MUiuPVI4PiEQvF2=	MkfKV2FPT0WU
MFH-ino	M2jybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlW3TWM2OD1zOD65OlY6KM7:TR?=	NWHzW4tSW0GQR1XS
D-263MG	NUPaVIZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2XIXWlEPTB;MUmuNFE4OiEQvF2=	NFjifXBUSU6JRWK=
NCI-H1437	NIfpboRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jYe2lEPTB;MUmuNFQ3PyEQvF2=	NGqwRnhUSU6JRWK=
NCI-H1048	Ml\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfrOWxKSzVyPUG5MlI{OjZizszN	MXzTRW5ITVJ?
NCI-H446	NILCT2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGnHUIVKSzVyPUG5MlM2QDlizszN	M{HqTXNCVkeHUh?=
NCI-N87	MlGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLPTWM2OD1zOT61PVkzKM7:TR?=	MUXTRW5ITVJ?
WM-115	NF3YPVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTF7Lk[3O\|Qh\|ryP	MmrwV2FPT0WU
HuH-7	NX;USVR2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmTETWM2OD1zOT63OFIyKM7:TR?=	MXTTRW5ITVJ?
NCI-H650	NEPo[2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnM[o9ZUUN3ME2xPU44PTB6IN88US=>	MlTXV2FPT0WU
TYK-nu	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{DLNmlEPTB;MUmuPFM4QCEQvF2=	M4Tlb3NCVkeHUh?=
Becker	NWDZWmdDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFG2ZpRKSzVyPUG5Mlg2PDdizszN	NH:3fodUSU6JRWK=
BB49-HNC	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTF7LkmyJO69VQ>?	NV\3U4kxW0GQR1XS
HGC-27	NUXrRWtWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTpTWM2OD1{MD6xN\|k1KM7:TR?=	NWTFUnpFW0GQR1XS
SiHa	NXz6d3lPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoLETWM2OD1{MD6zO\|EzKM7:TR?=	NWDBVmloW0GQR1XS
LB2518-MEL	NX;iemt4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEnjemVKSzVyPUKwMlM4OzlizszN	MUfTRW5ITVJ?
TE-5	NFvXNYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1vv[2lEPTB;MkCuO\|Q5OiEQvF2=	MVfTRW5ITVJ?
IST-SL1	NEK5UnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH7FVmhKSzVyPUKwMlc5PzlizszN	Mmj0V2FPT0WU
A375	MoXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3j5d2lEPTB;MkGuNFU3PyEQvF2=	NXT3e3hXW0GQR1XS
MC116	M{GzXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYnCV\|I{UUN3ME2yNU4xPzJ\|IN88US=>	NXPMRnRSW0GQR1XS
GI-1	NX\6S3RpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\xTWM2OD1{MT6xO{DPxE1?	MVrTRW5ITVJ?
HOP-62	MknmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHXSWpKSzVyPUKxMlI4QDRizszN	NXjYfXZyW0GQR1XS
PA-1	NILucZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{nuXGlEPTB;MkGuNlc5PyEQvF2=	NWPJXFdbW0GQR1XS
HT	NWHxU2VOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnnSTWM2OD1{MT60N\|MyKM7:TR?=	M3Py[HNCVkeHUh?=
HUTU-80	M2rG[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoPaTWM2OD1{MT60N\|M3KM7:TR?=	MYPTRW5ITVJ?
NCI-H1975	M3jpe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn3sTWM2OD1{MT60OlEh\|ryP	Mn6zV2FPT0WU
GAK	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2XUd2lEPTB;MkGuOFk6KM7:TR?=	NUPIcmlbW0GQR1XS
SK-N-AS	NH\PeG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWLE[GoxUUN3ME2yNU42PjF7IN88US=>	MUnTRW5ITVJ?
OE33	NFrjOGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDkeZBIUUN3ME2yNU43ODR4IN88US=>	M4W4bHNCVkeHUh?=
YKG-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPwUZZKSzVyPUKxMlY2PDVizszN	NF;JbYJUSU6JRWK=
CAL-85	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX:xeGZ{UUN3ME2yNU46OzB3IN88US=>	MVnTRW5ITVJ?
NCI-H2347	MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV:zU2N5UUN3ME2yNU46PDJ6IN88US=>	MkfzV2FPT0WU
PANC-08-13	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmL6TWM2OD1{Mj6wNVE6KM7:TR?=	MnPqV2FPT0WU
SK-N-FI	MorlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYfY[opbUUN3ME2yNk4{ODd2IN88US=>	MXLTRW5ITVJ?
NEC8	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGD2fnRKSzVyPUKyMlUxPzhizszN	NV3CdotYW0GQR1XS
AN3-CA	MlTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTJ{Lk[wPFQh\|ryP	M3PObnNCVkeHUh?=
HuO9	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3noOmlEPTB;MkKuO\|M6PiEQvF2=	NHzBR2RUSU6JRWK=
COLO-800	MlHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk\RTWM2OD1{Mj63OlU{KM7:TR?=	NEjYb3NUSU6JRWK=
HT-29	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHBTWM2OD1{Mj64PFI{KM7:TR?=	M3T6THNCVkeHUh?=
OC-314	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX65OWtMUUN3ME2yNk45QDR3IN88US=>	M{fPTnNCVkeHUh?=
G-401	NVrqNXd3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2DKVWlEPTB;MkOuNFQ3OiEQvF2=	NU\ZPGMzW0GQR1XS
Saos-2	NXjJfoNtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2TuO2lEPTB;MkOuOVE5OiEQvF2=	NHnoZ2FUSU6JRWK=
UACC-62	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlywTWM2OD1{Mz61PFM{KM7:TR?=	NWTxeFJZW0GQR1XS
D-247MG	MlHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DqZWlEPTB;MkOuO\|k{QSEQvF2=	M{nYRXNCVkeHUh?=
COLO-741	M3HrN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIT4[Y5KSzVyPUKzMlk2PjVizszN	M2T5bXNCVkeHUh?=
ES3	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYmzVYdrUUN3ME2yOE4xODJ\|IN88US=>	MkLDV2FPT0WU
LNCaP-Clone-FGC	MoHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nsSmlEPTB;MkSuNFIyOSEQvF2=	NF\PO4xUSU6JRWK=
SW1710	M33uPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHG[\|BzUUN3ME2yOE4yPTB4IN88US=>	NEG4cI9USU6JRWK=
LU-99A	NYq1N\|hZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXf4e5ozUUN3ME2yOE4yQDRzIN88US=>	MUTTRW5ITVJ?
HOP-92	NVTlbWp7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXrqcXRWUUN3ME2yOE44OjVizszN	M{XyfnNCVkeHUh?=
LS-123	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTJ2Lkm2NVQh\|ryP	NHfhbWZUSU6JRWK=
T84	NIT6Z45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2HKXWlEPTB;MkSuPVc3PSEQvF2=	Mm\MV2FPT0WU
HCT-116	NV\O[nk1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2jBU2lEPTB;MkWuOFE5PiEQvF2=	M2rhNXNCVkeHUh?=
M14	MmfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHnwXG5KSzVyPUK1MlQ1PDdizszN	NHexepBUSU6JRWK=
OCUB-M	M{nhTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnXhTWM2OD1{NT60OFU3KM7:TR?=	M1LwPXNCVkeHUh?=
MKN45	NVTF[pNXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPzTWM2OD1{NT62N\|E2KM7:TR?=	Mlq3V2FPT0WU
LCLC-97TM1	NYnVWZpIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3L0ZWlEPTB;MkWuO\|I5PSEQvF2=	NF:3[JJUSU6JRWK=
RVH-421	NF7lPGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTJ3LkixOlEh\|ryP	MWHTRW5ITVJ?
NKS-81-FD	NUfle4t7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M37NemlEPTB;MkWuPVAzOSEQvF2=	Mnm2V2FPT0WU
NCI-H596	NWDEfVZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\uTWM2OD1{Nj6wOFg4KM7:TR?=	NXPIUZBQW0GQR1XS
GB-1	MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTJ4LkG4O\|kh\|ryP	MkjKV2FPT0WU
ZR-75-30	NX:xRYJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2n2[WlEPTB;Mk[uNlI6PyEQvF2=	NEjLOJFUSU6JRWK=
U-2-OS	NXiyXIhLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTJ4LkO3OVch\|ryP	M4fDOXNCVkeHUh?=
HuP-T3	M3f0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MljyTWM2OD1{Nj62NVAzKM7:TR?=	MYLTRW5ITVJ?
MOLT-16	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHTibFJKSzVyPUK2MlYyPjZizszN	NXjOdY17W0GQR1XS
U-87-MG	NFX6bVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MormTWM2OD1{Nj63OFM5KM7:TR?=	M{nrV3NCVkeHUh?=
8505C	NFzpcHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXm2THB4UUN3ME2yOk46OTJ4IN88US=>	NEnrS45USU6JRWK=
SK-MEL-3	MmDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrTUFJKSzVyPUK2Mlk5OjhizszN	NX:5RlZtW0GQR1XS
COLO-824	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;sNWlEPTB;MkeuNlE6PSEQvF2=	NVPVbGlWW0GQR1XS
EW-1	NWTZfINuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlnDTWM2OD1{Nz6zOVU1KM7:TR?=	M1jVR3NCVkeHUh?=
UACC-257	MkPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPMfIpQUUN3ME2yO{4{QDB2IN88US=>	M4HEN3NCVkeHUh?=
Hs-578-T	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoS4TWM2OD1{Nz61Nlk6KM7:TR?=	M13wUnNCVkeHUh?=
UACC-893	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\PW3NKSzVyPUK3MlY3OzFizszN	MnjuV2FPT0WU
MHH-NB-11	MkTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVO1SXJYUUN3ME2yO{45ODB5IN88US=>	MWXTRW5ITVJ?
KYSE-410	NX;Ed3BST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml7tTWM2OD1{OD6yO\|c6KM7:TR?=	NWPK[JhEW0GQR1XS
SF126	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\uTWM2OD1{OD63OFM2KM7:TR?=	NInIXXZUSU6JRWK=
HT-144	MnTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorSTWM2OD1{OT6zN\|YzKM7:TR?=	MoXtV2FPT0WU
SW1573	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHKTWM2OD1{OT6zOVA6KM7:TR?=	NXTmO\|VVW0GQR1XS
SW620	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYjqfpNOUUN3ME2yPU4{PjRzIN88US=>	NVPTcIVFW0GQR1XS
SCH	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\yTWM2OD1{OT64PFMyKM7:TR?=	Ml;QV2FPT0WU
EW-22	M3POW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHfNcXVKSzVyPUOwMlE6PjlizszN	NEPXPHVUSU6JRWK=
H4	NYnnV49yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\wcXpKSzVyPUOwMlQ3PTRizszN	NITR[G1USU6JRWK=
CAS-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFTLeIVKSzVyPUOwMlc5PTlizszN	Ml7iV2FPT0WU
MG-63	NIfDW4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvCTWM2OD1\|MD64OFc5KM7:TR?=	NIXabJdUSU6JRWK=
MDA-MB-415	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTNzLkG3OVMh\|ryP	NYLjXYJNW0GQR1XS
NCI-H1395	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\qTWM2OD1\|MT6yN\|I5KM7:TR?=	MUDTRW5ITVJ?
Ca-Ski	NYXYcHJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTBXHFrUUN3ME2zNU4{OTd5IN88US=>	NEn1NXNUSU6JRWK=
BxPC-3	MnrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nUcWlEPTB;M{GuN\|czQSEQvF2=	NF23W45USU6JRWK=
A3-KAW	M{PFWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXHJR\|UxRTNzLkS0O\|Eh\|ryP	MUfTRW5ITVJ?
T-24	MnLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXnTWM2OD1\|MT63N\|YzKM7:TR?=	MVfTRW5ITVJ?
NCI-H2029	NG\SfohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTNzLke3OlUh\|ryP	MmHzV2FPT0WU
YAPC	M1;XNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nOfmlEPTB;M{KuNFQxPyEQvF2=	NGXSR49USU6JRWK=
SK-MEL-2	MnnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFHDRpRKSzVyPUOyMlA2OiEQvF2=	MlzuV2FPT0WU
LS-513	MlPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlzPTWM2OD1\|Mj6xNVg4KM7:TR?=	M3nqcnNCVkeHUh?=
AsPC-1	NWfRWYxET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRTN{LkO2NFUh\|ryP	Mm\ZV2FPT0WU
KYSE-150	M2TnNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHO1fWhKSzVyPUOyMlM4PzNizszN	M{TBXnNCVkeHUh?=
NCI-H520	Ml7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{f4WGlEPTB;M{KuOFQ5OiEQvF2=	MljiV2FPT0WU
JEG-3	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWLwWZdwUUN3ME2zN{4xQTdzIN88US=>	MXTTRW5ITVJ?
GMS-10	NYrFV5NZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTN\|LkOwNFQh\|ryP	M{jmO3NCVkeHUh?=
HT-1080	NEjUXXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTN\|LkO5JO69VQ>?	MV3TRW5ITVJ?
NCI-H1651	M4jTWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml7JTWM2OD1\|Mz6zPVYh\|ryP	NH7ONGVUSU6JRWK=
NCI-H2122	MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MomwTWM2OD1\|Mz61OVc1KM7:TR?=	MkPJV2FPT0WU
ES5	NYH1N2dJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{PCRmlEPTB;M{OuO\|I6OiEQvF2=	NF3tNWdUSU6JRWK=
8305C	NGXKdJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2nKPWlEPTB;M{OuPVk{PyEQvF2=	MnzQV2FPT0WU
KM12	NIDVOZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NInEWmxKSzVyPUO0MlA1PzhizszN	MkLnV2FPT0WU
HCT-15	NYnOdGhuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLQbGhKSzVyPUO0MlEzPyEQvF2=	M{XDVnNCVkeHUh?=
OVCAR-5	M3e1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlLlTWM2OD1\|ND6yNVgzKM7:TR?=	MnXZV2FPT0WU
NCI-H2291	NYDZfmtZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnHNTWM2OD1\|ND6yOFczKM7:TR?=	NXPqTGYxW0GQR1XS
CP50-MEL-B	NXj2fY1UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEHDNVRKSzVyPUO0MlY2QTJizszN	NIDhPI5USU6JRWK=
C-33-A	M3Oz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkDUTWM2OD1\|ND62PFU4KM7:TR?=	MlfFV2FPT0WU
NCI-H2452	MmHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2myO2lEPTB;M{SuO\|g5OiEQvF2=	M1jVT3NCVkeHUh?=
MDA-MB-157	NYG2NYc1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmXOTWM2OD1\|ND64NVk{KM7:TR?=	NYDpWIhCW0GQR1XS
LN-405	MnT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTN3LkSzNFgh\|ryP	NXzxN3hOW0GQR1XS
MDA-MB-231	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXf3PFR6UUN3ME2zOU42ODV2IN88US=>	NHvJbmdUSU6JRWK=
EW-24	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTN3Lk[zN\|Uh\|ryP	MoLSV2FPT0WU
MKN28	M1TzSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTYTWM2OD1\|NT64NlM3KM7:TR?=	MXPTRW5ITVJ?
KINGS-1	NFPsV4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGLqOXRKSzVyPUO1Mlg1OzRizszN	NIKzZYFUSU6JRWK=
LC-2-ad	M4XUc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoOzTWM2OD1\|Nj62PVkh\|ryP	MU\TRW5ITVJ?
IGR-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4P1dmlEPTB;M{[uO\|A4PSEQvF2=	MWLTRW5ITVJ?
SW626	MmDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorRTWM2OD1\|Nz6wOFE4KM7:TR?=	MV7TRW5ITVJ?
ONS-76	M{DWVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWLSWIVqUUN3ME2zO{4yOzB7IN88US=>	NXe2NJVlW0GQR1XS
T98G	M4\xeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1G2cGlEPTB;M{euPFY{PSEQvF2=	NYfNUmczW0GQR1XS
NB14	MmfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2f1UmlEPTB;M{iuOFU1PCEQvF2=	NWXocHh5W0GQR1XS
D-423MG	NY\FSJprT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkPxTWM2OD1\|OD60PFY6KM7:TR?=	MmXWV2FPT0WU
NCI-H510A	NHPC[JNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1HWUmlEPTB;M{iuOlQ2OSEQvF2=	M2DNdHNCVkeHUh?=
NMC-G1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTN6LkeyNlIh\|ryP	Mn3oV2FPT0WU
SW948	NIOzOFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTN6Lki5OFkh\|ryP	M3LYOXNCVkeHUh?=
MFM-223	NUi3N45yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHtRVJKSzVyPUO4Mlk1OzFizszN	NYHRRpJVW0GQR1XS
PAN1	MoK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MojuTWM2OD1\|OD65PVE6KM7:TR?=	NFmwfFFUSU6JRWK=
MZ7-mel	Ml\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEDFNVdKSzVyPUO5MlEyQTlizszN	M3nX[3NCVkeHUh?=
COLO-679	NXzPVIJlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XlPGlEPTB;M{muPVcxQCEQvF2=	NUnjRW9PW0GQR1XS
SW872	M13lWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{DaZ2lEPTB;NECuNlA{OSEQvF2=	MVrTRW5ITVJ?
HT-1197	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXmdHdkUUN3ME20NE4zQDZ7IN88US=>	NWixW3E5W0GQR1XS
ES6	M2jlRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{P0PWlEPTB;NECuOFU2OiEQvF2=	NF\WcnhUSU6JRWK=
SNU-387	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TxVWlEPTB;NECuPFI{QCEQvF2=	MYPTRW5ITVJ?
T47D	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MonLTWM2OD12MT6wNVkzKM7:TR?=	NHPLOpZUSU6JRWK=
G-402	M3W3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3PJemlEPTB;NEGuNFgxQSEQvF2=	MkPMV2FPT0WU
MZ1-PC	MlK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4XCdGlEPTB;NEGuPFEh\|ryP	MWTTRW5ITVJ?
SW1417	NIfhW5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXrmbIp4UUN3ME20Nk4{ODNizszN	MlLXV2FPT0WU
RERF-LC-MS	MlXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF7LNW1KSzVyPUSyMlUxQDdizszN	Mn\yV2FPT0WU
SF539	NHTMUZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTR{LkW1Nlkh\|ryP	NXPVb5VyW0GQR1XS
ESS-1	MlOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2C3OmlEPTB;NEOuOVU2QCEQvF2=	M4P4NnNCVkeHUh?=
RO82-W-1	Ml\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWPJR\|UxRTR\|Lk[xOVMh\|ryP	MVvTRW5ITVJ?
S-117	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2fWd2lEPTB;NEOuOlk2QCEQvF2=	NGS3dlRUSU6JRWK=
SW756	NXL5Uo12T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4W1bmlEPTB;NEOuPFI1OiEQvF2=	NFqxN\|hUSU6JRWK=
CP66-MEL	NWi1emo4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2n1e2lEPTB;NEWuO\|E1OyEQvF2=	M4f4WXNCVkeHUh?=
H-EMC-SS	NXe1THE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEW4OoVKSzVyPUS1Mlc3QTNizszN	NGLQXIlUSU6JRWK=
NCI-H2052	M2nudmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXjJR\|UxRTR3LkmwNlch\|ryP	MlLYV2FPT0WU
SW684	NWrnN3pWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFi5VIdKSzVyPUS3MlAxQDFizszN	M2LUNnNCVkeHUh?=
HCC1569	NVvoR3RxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2HWfWlEPTB;NEeuNVY2QCEQvF2=	NWTreohYW0GQR1XS
KGN	NGTFdIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3TLNGlEPTB;NEeuN\|MyOSEQvF2=	NUP4SFE6W0GQR1XS
LCLC-103H	NYe1OohrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYGyeItLUUN3ME20O{41PDB2IN88US=>	NFL1ZXlUSU6JRWK=
SW780	NHPHVXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3zZVWlEPTB;NEeuOlM2OSEQvF2=	MkLIV2FPT0WU
NCI-H1703	NX;ofGwxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;IRnhKSzVyPUS4MlM{PTJizszN	NHXwXWFUSU6JRWK=
HCC1395	M{PENGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rqU2lEPTB;NEiuO\|Q{OiEQvF2=	MYXTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-EGFR / phospho-ERK / phospho-SRC / phospho-AKT; PubMed: 22586683 Cancer Discov Effect of overexpressing CRKL on phosphorylation levels of EGFR, ERK, AKT and SRC in response to gefitinib. HCC827 cells expressing a control vector or CRKL were exposed to gefitinib at indicated concentrations for 6 h and cell lysates were collected for immunoblotting with indicated specific antibodies. Cyclin D1/ p16 / p27 / pRb; PubMed: 18559346 J Biol Chem levels of phosphorylated and total EGFR, IGF-1R, Akt, ERK1/2, and Rb and levels of cyclin D1, p27, p16, and actin following 6- or 16-h treatment of A431 cells with combinations of 1 or 3 μm gefitinib and 3 μm NVP-ADW742. Data are representative of two independent experiments. uc-caspase-9 / c-caspase-9 / uc-caspase-3 / c-caspase-3 / uc-PARP / PARP; PubMed: 23102728 Mol Oncol Apoptosis resulting from combined treatment with gefitinib and an MEK inhibitor. (A) apoptosis relating protein induced by gefitinib and/or AZD6244 in PC‐9/wt and PC‐9/gef B4 cells. (B) Apoptosis relating protein induced by gefitinib and/or CI‐1040 in PC‐9/wt and PC‐9/gef B4 cells. (C) apoptosis relating protein induced by gefitinib and/or AZD6244 in PC‐9/gefE3 and PC‐9/gefE7 cells. (D) apoptosis relating protein induced by gefitinib and/or CI‐1040 in PC‐9/gefE3 and PC‐9/gefE7 cells. PPAR-γ; PubMed: 23409107 PLoS One Fold increase relative to control was determined after normalization with β-actin as external loading control.	22586683 18559346 23102728 23409107
Immunofluorescence	EGFR / LC3; PubMed: 31196210 J Exp Clin Cancer Res H157 and H1299 cells were treated with gefitinib, or curcumin alone, or gefitinib plus curcumin at indicated concentration for 48 h and then were fixed with methanol, immunostained with anti-EGFR (green), anti-LC3 (red), and DAPI (blue), and analyzed by confocal microscopy to determine the intracellular locations of EGFR and LC3. PPAR-γ; PubMed: 23409107 PLoS One Upregulation and nuclear accumulation of PPARγ following treatment with gefitinib (24 hs). p-EGFR / β-catenin; PubMed: 23461856 FEBS J In untreated CNE2 cells, β-catenin was located in cytoplasmic membranes and cytoplasm. Treatment with EGF (50 ng/mL) resulted in increased β-catenin nuclear staining, which was reversed by either gefitinib (1 μM) or LY294002 (15 μM).	31196210 23409107 23461856
Growth inhibition assay	GI50; PubMed: 23409107 PLoS One Dose-response of bladder cancer cell lines to EGFR inhibitor (gefitinib). The GI50 value was defined as the mean concentration of drug that generates 50% of growth inhibition as compared to controls.	23409107

In vivo

Gefitinib (100 mg/kg) improves the anti-tumor effect of radiotherapy in LoVo tumor xenografts. ^[3] Gefitinib treatment of nude mice bearing established human GEO colon cancer xenografts reveals a reversible dose-dependent inhibition of tumor growth because GEO tumors resumes the growth rate of controls at the end of the treatment. ^[4]

Protocol

Cell Research:^[1]	+ Expand Cell lines: NR6, NR6M and NR6W cells Concentrations: 0-2 μM Incubation Time: 72 hours Method: Exponentially growing cells including NR6, NR6M, NR6M and NR6W cells are seeded in sextuple in 96-well plates at a concentration of 2000 cells/well, allowed to adhere and subsequently washed in PBS and incubated overnight in medium containing 0.5% FCS. Cells are then treated with varying concentrations (0-2 μM) of Gefitinib or the solute control DMSO and EGF. The optimal EGF concentration for inducing proliferation of NR6wtEGFR and NR6W cells has previously been determined and hence NR6wtEGFR and NR6W cells are supplemented with 10 nM and 0.1 nM EGF, respectively. EGF is not added to NR6 and NR6M cells. After 72 hours the amount of cells are measured by performing a MTT proliferation assay. (Only for Reference)
Animal Research:^[3]	+ Expand Animal Models: Female nude mice (cba nu/nu) aged 8–10 weeks are intra-dermal injected with LoVo cells. Formulation: 0.5% polysorbate Dosages: 100 mg/kg Administration: Once daily by oral administration (0.1 mL/10 g body weight) for 14 days (Only for Reference)

Cell Research:^[1]

+ Expand

Cell lines: NR6, NR6M and NR6W cells
Concentrations: 0-2 μM
Incubation Time: 72 hours
Method: Exponentially growing cells including NR6, NR6M, NR6M and NR6W cells are seeded in sextuple in 96-well plates at a concentration of 2000 cells/well, allowed to adhere and subsequently washed in PBS and incubated overnight in medium containing 0.5% FCS. Cells are then treated with varying concentrations (0-2 μM) of Gefitinib or the solute control DMSO and EGF. The optimal EGF concentration for inducing proliferation of NR6wtEGFR and NR6W cells has previously been determined and hence NR6wtEGFR and NR6W cells are supplemented with 10 nM and 0.1 nM EGF, respectively. EGF is not added to NR6 and NR6M cells. After 72 hours the amount of cells are measured by performing a MTT proliferation assay.
(Only for Reference)

Animal Research:^[3]

+ Expand

Animal Models: Female nude mice (cba nu/nu) aged 8–10 weeks are intra-dermal injected with LoVo cells.
Formulation: 0.5% polysorbate
Dosages: 100 mg/kg
Administration: Once daily by oral administration (0.1 mL/10 g body weight) for 14 days
(Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	89 mg/mL (199.14 mM)
	Ethanol	4 mg/mL (8.95 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% CMC Na For best results, use promptly after mixing.	30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Gefitinib (ZD1839) SDF

Molecular Weight	446.90
Formula	C₂₂H₂₄ClFN₄O₃
CAS No.	184475-35-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03866499	Not yet recruiting	NSCLC	Beta Pharma Inc.	May 2019	Phase 3
NCT03866499	Not yet recruiting	NSCLC	Beta Pharma Inc.	May 2019	Phase 3
NCT03787992	Not yet recruiting	Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer	Allist Pharmaceuticals Inc.	April 1 2019	Phase 3
NCT03787992	Not yet recruiting	Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer	Allist Pharmaceuticals Inc.	April 1 2019	Phase 3
NCT03766490	Not yet recruiting	Non-Small-Cell Lung	The First Affiliated Hospital of Soochow University\|The First People''s Hospital of Changzhou\|Second Affiliated Hospital of Soochow University\|Nantong University\|Affiliated Hospital of Jiangnan University\|Jiangyin People''s Hospital\|Changzhou No.2 People''s Hospital\|Chia Tai Tianqing Pharmaceutical Group Co. Ltd.	March 30 2019	Not Applicable
NCT03856697	Not yet recruiting	Advanced Non-small Cell Lung Cancer	Hangzhou ACEA Pharmaceutical Research Co. Ltd.\|Guangdong Provincial People''s Hospital	March 2019	Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I try to dissolve Gefitinib (ZD1839) in 0.5% methylcellulose+0.2% Tween 80 for in vivo experiments. However, when I prepare the mixture, it forms precipitates. Exists another way to dissolve completely the compound?
Answer:
S1025 can be dissovled in both 5% DMSO+corn oil and 5% DMSO+30% PEG 300+5% Tween 80+ddH2O at 2.5 mg/ml clearly. It dissolves in DMSO not readily, please sonicate and warm it in water bath at about 45 degree, and dissolve it clearly first. Then add other solvent.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Pan EGFR Inhibitor

AZD8931 (Sapitinib) : Pan-ErbB inhibitor, EGFR/ErbB2/ErbB3, IC50=4 nM/3 nM/4 nM.
Most Potent EGFR Inhibitor

Afatinib (BIBW2992) : EGFR(wt), IC50=0.5 nM; EGFR(L858R), IC50=0.4 nM; EGFR(L858R/T790M), IC50=10 nM; HER2, IC50=14 nM.
FDA-approved EGFR Inhibitor

Lapatinib : Approved by FDA for breast cancer.
Newest EGFR Inhibitor

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

Related EGFR Products4

Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992) Dimaleate ^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.
Poziotinib (HM781-36B) ^New

Poziotinib (HM781-36B) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Phase 2.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992)

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively.
Osimertinib (AZD9291)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Lapatinib

Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.
AG-490 (Tyrphostin B42)

AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Rociletinib (CO-1686, AVL-301)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.
AG-1478 (Tyrphostin AG-1478)

AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.

Choose Your Country or Region

By Signaling Pathways

By product type

Gefitinib (ZD1839)

Cited by 98 Publications

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Gefitinib (ZD1839) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Related EGFR Products4

Choose Your Country or Region

By Signaling Pathways

By product type

Gefitinib (ZD1839)

Cited by 98 Publications

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Gefitinib (ZD1839) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Related EGFR Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)